Delivering strong (1)H nuclear hyperpolarization levels and long magnetic lifetimes through signal amplification by reversible exchange. by Rayner, PJ et al.
Delivering  Strong 1H Nuclei Hyperpolarization Levels and Long Magnetic 
Lifetimes through Signal Amplification by Reversible Exchange 
Peter J. Rayner, Michael  J. Burns, Alexandra M. Olaru, Philip Norcott, Marianna Fekete, Gary G. R. Green, Louise A. 
R. Highton, Ryan. E. Mewis and Simon. B. Duckett* 
Centre for Hyperpolarisation in Magnetic Resonance, Department of Chemistry, University of York, Heslington, YO10 5NY  
Hyperpolarization turns typically weak NMR and MRI responses into 
strong signals so that ordinarily impractical measurements become 
possible. The potential to revolutionize analytical NMR and clinical 
diagnosis through this approach reflect this area's most compelling 
outcomes. Methods to optimize the low cost parahydrogen based 
signal amplification by reversible exchange (SABRE) approach 
through studies on a series of biologically relevant nicotinamides 
and methyl nicotinates are first detailed. These procedures involve 
specific 2H-labelling in both the agent and catalyst and achieve 
polarization lifetimes of ca. 2 minutes with 50% detectability in the 
case of 4,6-d2-nicotinate. As a 1.5 T hospital scanner has an 
effective 1H detectability level of just 0.0005% this strategy should 
result in compressed detection times for chemically discerning 
measurements that probe disease. To demonstrate this techniques 
generality, we exemplify further studies on a range of pyridazine, 
pyrimidine, pyrazine and isonicotinamide analogues that feature as 
building blocks in biochemistry and many disease treating drugs.  
Hyperpolarization | SABRE | Catalysis | NMR | MRI 
Introduction 
By harnessing the magnetic properties of nuclei, we unlock 
nuclear magnetic resonance (NMR), one of the most powerful 
methods available for studying materials, which in the form of 
magnetic resonance imaging (MRI) revolutionizes  clinical 
diagnosis.(1) One simple route to improve the diagnostic 
capabilities of MRI involves monitoring in vivo changes in 
metabolite flux in conjunction with spatially resolved 
measurements to non-invasively probe human physiology.(2) 
However, for reasons of low sensitivity, agent detection needs 
to be coupled with approaches to increase detectability.(3) This 
process is exemplified by studies on pyruvate which harnesses 
dissolution dynamic nuclear polarization (DNP)(4) to produce 
the signal strength necessary to track its metabolism. 
Additionally, the related method of optical pumping noble gases, 
such as 129Xe,(5) has provided the sensitivity needed to produce 
lung MR images that probe pulmonary disease.  
Both of these agents magnetic resonance (MR) detectability was 
greatly increased through a process known as hyperpolarization. 
However, the associated hyperpolarization step could be viewed 
as being complex.(6, 7) One related method of great promise is 
that of MR enhancement by parahydrogen (p-H2).(8, 9) p-H2 is a 
unique hyperpolarized feedstock which has no magnetic 
moment and is not observed itself.(10) Instead, a highly visible 
agent is obtained when it adds to an unsaturated center as a 
consequence of this chemical change.(10) The resulting 
products’ intrinsic magnetization, more commonly referred to as 
polarization, can lie so far from thermodynamic equilibrium that 
measurements which normally take months become possible in 
seconds.(11) However, this is only possible if the agent's high-
sensitivity monitoring takes place before relaxation returns its 
polarization to the more usual weak-signal level. Moreover, the 
associated magnetization can be examined just once at high 
sensitivity because the hyperpolarization process takes place 
outside the final readout-area. Hence the imaging of such agents 
after dosing in a clinical setting must be very rapid if the strong 
response is to survive the time taken to travel to this location. 
The development of this technique is, therefore fraught with 
experimental challenge as fresh samples are needed for each 
study. Furthermore, the use of NMR spectroscopy as an 
analytical tool would also benefit substantially if the materials it 
analyses can be rapidly characterized at lower concentrations 
than is currently possible.(12-14) Hence, harnessing the fruits of 
hyperpolarization will provide opportunities to improve our 
ability to study materials in a very wide range of applications.  
 
In this study, we illustrate a number of new developments to 
dramatically improve the p-H2 based method Signal 
Amplification By Reversible Exchange (SABRE).(15) This route 
shows great promise for contributing significantly to both 
analytical NMR and clinical diagnosis in the future.(16-21) SABRE 
does not change the chemical identity of the agent it 
hyperpolarizes, it simply equilibrates polarization between p-H2 
and the selected agent to create highly visible signals through 
earlier binding to a metal center.(15) This simple and cheap to 
implement process is shown schematically in Fig. 1 with the 
reproducible response being created in just a few seconds.(22) 
Furthermore, as it maintains its hyperpolarization while in the 
presence of p-H2 it can maintain its polarization level for many 
Significance  
The study of molecules and materials is of great significance to 
both science and human life, with non-invasive techniques such as 
nuclear magnetic resonance and magnetic resonance imaging 
reflecting some of the most important methods for probing them.  
However, both of these approaches are inherently insensitive and 
would benefit greatly from improved signal strengths. A strategy 
to optimize the Signal Amplification by Reversible Exchange 
(SABRE) is presented here that can improve signal strengths by 
over 100,000 times those which would be seen on a routine 
clinical MRI scanner after just 10 seconds of exposure to 
parahydrogen. Furthermore, by revealing the broad scope of this 
approach we demonstrate its potential for the future diagnostic 
detection of materials, metabolites or drugs by NMR or MRI. 
minutes in low field as it can be continually replenished (22, 23). 
Consequently we predict that the future in vivo optimization of 
this method will be easier than that of many other approaches if 
we can deliver agents with high signal strengths and 
appropriately long-lived magnetization. 
 
Fig. 1. Schematic representation of the SABRE effect 
We present here a general strategy to achieve this aim by 
combining a series of breakthroughs in substrate and catalyst 
design. We illustrate this strategy through studies on 
nicotinamide (1) and methyl nicotinate (2), and a series of their 
selectively deuterated analogues, before demonstrating the 
approaches wider applicability. These two agents exhibit low 
toxicity and play  important roles in cellular biology and hence 
are biochemically important targets.(24) The relaxation times 
and hyperpolarization levels of these biocompatible agents are 
shown to be dramatically increased by the selective use of spin-
dilution through appropriate 2H-labelling, a strategy that has 
already be deployed for DNP.(25) We overcome the fact that the 
SABRE catalyst ultimately reduces the levels of hyperpolarization 
through transfer to H2 when p-H2 is a limiting reagent(26) by 
improving on the lifetime of the agents’ magnetization when 
bound to the catalyst through 2H-labelling of its ancillary ligands. 
Subsequently, we show that by combining these strategic 
advances 50% hyperpolarization can be achieved in conjunction 
with magnetic-state lifetimes that approach 100 seconds for a 
2H-labelled nicotinate. By expanding the scope of this strategy to 
other target agents we show that a universal improvement in 1H 
hyperpolarization level and relaxation time is achieved. The 
single-scan MRI detection of these agents is then used to reveal 
that these improvements facilitate the acquisition of images 
whose intensity and contrast are vastly superior to those 
without hyperpolarization. Whilst the relaxation times of these 
agents are reduced in H2O solution, they still exhibit high 
detectability when compared to the results of normal study. 
Hence we are confident that the results presented here reflect a 
series of key steps towards successful in vivo SABRE whilst also 
serving to improve its potential as analytical tool for NMR.  
Results and discussion  
The SABRE method starts by dissolving an agent (substrate) in a 
solvent that contains a metal based polarization transfer catalyst 
and then exposing it to p-H2 for a few seconds in low magnetic 
field. The hyperpolarized agent can then be detected in a second 
step by NMR or MRI methods. Protio-nicotinamide (1) was one 
of the first substrates to be polarized by SABRE(15) and aspects 
of its 1H, 13C and 15N signal enhancement have been previously 
communicated.(27-31). When 1 is hyperpolarized in this way 
through SABRE(28) in methanol-d4 solution, as detailed in the 
supporting information, the signal for H-2 is ca. 650 times larger 
than that observed in a control measurement under Boltzmann 
conditions at a 9.4 T field. In contrast, the corresponding signals 
for H-4, H-5 and H-6 are 620, 190 and 590 times larger 
respectively than those of the H-2 control signal. Fig. 2-left 
illustrates a typical measurement. This signal intensity 
corresponds to detecting 2.1% H-2 polarization, created after a 
combination of just 7 seconds exposure to 3 bar of p-H2 and 
three seconds for subsequent transfer into the measurement 
field. The corresponding polarization values in ethanol-d6 range 
from 1.1 to 0.1% as detailed in Table 1. It is therefore 
straightforward to conclude that 1 is highly amenable to SABRE. 
Furthermore, according to the laws of signal averaging, if 31 
seconds were needed to repeat each control measurement, it 
would take ca. 150 days of data collection to reproduce the 
previously detailed hyperpolarized result if a normal signal were 
to be employed. It is for this reason that hyperpolarization 
represents a platform that could radically transform clinical 
diagnosis and analytical NMR more generally. 
  
Fig. 2. SABRE hyperpolarization of nicotinamide: Left: Single scan 1H 
NMR traces, with identical scaling, that illustrate nicotinamide (1) signals 
(as labelled) that result after SABRE (hyperpolarized) and when the 
polarization level matches that for thermodynamic equilibrium (normal). 
Right: Similar single scan 1H NMR traces employing 1e (Table 1); the 
normal trace has a x8 vertical expansion relative to the hyperpolarized 
trace (all measurements were performed in ethanol-d6). 
As we have indicated though, this signal gain must survive to the 
point of measurement. In methanol-d4 solution, the four distinct 
protons resonances of 1, H-2, H-4, H-5 and H-6, have T1 values of 
16.3, 11.3, 6.9 and 9.8 seconds at 9.4 T respectively (see Table 1, 
errors are <5% unless specified). These T1 values change to 23.3 
(50% increase), 6.7 (40% fall), 3.9 (45% fall) and 7.8 (20% fall) 
seconds respectively in ethanol-d6 solution, and range from 10.7 
to 6.5 seconds in D2O solution. Hence these values are highly 
solvent dependent and not, at first glance, likely to be ideal for 
in vivo imaging; due to low SABRE efficiency in neat D2O 
solutions the corresponding polarization levels are not 
reported.(32, 33)  
Relaxation during SABRE catalysis 
Examination of these NMR relaxation properties under  SABRE 
conditions reveals that the observed T1 values for the four 
proton signals of 1 reduce to just 6.2, 6.3, 3.7 and 3.8 seconds 
respectively in methanol-d4. Furthermore, the H-2 T1 value in 
ethanol-d6 falls by 83% to 4.2 seconds thereby implying even 
faster signal destruction. These changes are explained by the 
role the SABRE catalyst plays in facilitating the reversible flow of 
polarization according to Fig. 1. During SABRE, rapid polarization 
transfer is beneficial, in leading to a large signal gain but at high 
field, or without p-H2, the catalyst clearly destroys the contrast 
agents’ hyperpolarization by reducing T1.  
Using 2H-labelling to reduce agent relaxation  
Initially, we proposed to overcome these effects by using 2H-
labelling to extend the proton relaxation times of 1.(27)  Hence, 
nicotinamide derivatives 1a-1g were prepared using the 
methods described in Fig. 3. These synthetic routes have been 
scaled to provide over 25 grams of the desired isotopologue and 
thus provide a robust platform to underpin any potential 
clinical/pre-clinical studies. Table 1 presents their SABRE 
performance and proton T1 values, both with and without 
catalyst, at 9.4 T in methanol-d4, ethanol-d6 and D2O solutions 
and clearly there is a beneficial extension in T1.  
 
Fig. 3. Synthetic methods used to prepare agents 1a-1g. Yields are isolated 
yields after column chromatography. 
As these structures all contain fewer protons than 1, they might 
be expected to achieve higher polarization levels under 
conditions when p-H2 is the limiting reagent. However, substrate 
1a, whose ortho protons have been removed, gives low 
polarization under SABRE conditions. We conclude, therefore, 
that 1a has polarization acceptor sites that are too magnetically 
isolated from the hydride ligands of the catalyst for effective 
SABRE transfer. In contrast, forms 1b-1g all possess a proton 
adjacent to nitrogen, and based on the recent study by Tessari 
et al., the relative position of the ortho proton to the ring 
substituent is unlikely to affect its coupling with the hydride 
ligand in the catalyst.(34) They should therefore all receive 
polarization at a similar rate and hence the poor performance of 
1c under SABRE must be a consequence of rapid relaxation. 
Agents 1e and 1f have the largest average T1 values of the series 
and perform best under SABRE. 1e possesses a 4J coupling 
between protons H-4 and H-6 that facilitates magnetization 
transfer between them and gives hyperpolarization levels of 2.7 
and 3.2% respectively in methanol-d4 (Fig. 1). For 1f, the 
corresponding weaker 5J coupling between protons H-2 and H-5 
now results in 4.1% hyperpolarization levels. 1d, with a 4J, and 
1b with a 3J coupling, and triply 2H-labelled 1g also perform less 
well than 1e and 1f which can readily be explained by their poor 
T1 values. Hence we conclude that locating one proton next to 
the N-binding site (for strong coupling to the hydride ligands) 
and a longer-range coupling to a second longer-lived storage site 
is optimal.  
Optimizing the SABRE catalysis of methyl nicotinate 
As the amide protons of nicotinamide are likely to play a role in 
these relaxation processes the series of related methyl 
nicotinates 2a-2e, shown in Table 2, were prepared and studied. 
The parent, protio-nicotinate 2, proved to be superior to 1 under 
SABRE catalysis, with its four aromatic proton resonances 
showing an average polarization level of 2.7% in methanol-d4 
and 1.7% in ethanol-d6 under our test; transfer to the methyl 
group is negligible. Furthermore, proton H-2 now has a T1 value 
of 60 seconds in methanol-d4, 49 seconds in ethanol-d6 and 13.8 
seconds in D2O. In contrast, doubly 2H-labelled 4,6-d2-nicotinate 
(2b) has proton T1 values in the absence of the catalyst for H-2 
of 66 seconds and H-5 of 97.6 seconds in methanol-d4. These 
drop to 46.2 and 62.7 seconds respectively in ethanol-d6, but 
retain impressive values of 30.9 and 47.4 seconds in D2O. As a 
consequence of these changes we boost the delivered SABRE 
polarization levels to 10.1% and 9.5% respectively in methanol 
whilst retaining an average hyperpolarization level of ca. 8.75% 
in ethanol-d6. It proved possible to improve on these already 
impressive results by introducing a CD3 label such that d3-methyl 
4,6-d2-nicotinate (2c) exhibits T1 values of 50.1 and 50.3 seconds 
in D2O whilst achieving 7.2% polarization in ethanol-d6.  
Improving the SABRE catalyst through 2H-labelling  
The presence of the catalyst acts to reduce the measured T1 
values of the protons of the free substrate because the bound 
and free forms of the substrate are in dynamic exchange and 
consequently the recorded protons’ T1 values must reflect their 
appropriately weighted average. Hence, the T1 value of a bound 
proton must be much smaller than the real value of the free 
material. We proved this by measuring the bound and free 
protons relaxation times at 263 K where ligand exchange is 
effectively quenched (see supporting information). We 
hypothesized that the slow rate of productive polarization 
transfer(15) means that any increase in the bound protons' 
relaxation times would be seen in an improved final agent 
polarization level. Conceptually, this could also be achieved by 
introducing 2H-labelling into the N-heterocyclic carbene (NHC) 
ligand of the catalyst. Thus, we developed synthetic routes (see 
supporting information) to produce d2-, d22- and d24-IMes ligands 
which were used to form the corresponding [IrCl(COD)(NHC)] 
catalyst (Fig. 4). The measured T1 values of the protons in 2b 
(bound and free) with these catalyst isotopomers, under 3 bar of 
H2 or D2, in methanol-d4 solution are detailed in Table 3.  
 
Fig. 4: 2H-Labelled NHC ligands used for SABRE polarization with catalysts of 
type [IrCl(COD)(NHC)] 
These data show that as predicted the T1 values of the H-2 
resonance in equatorially bound 2b is increased by 36% on 
moving from H2 to D2 respectively at 263 K. This confirms that 
coupling to the hydride ligands provide a significant route to 
relaxation. Furthermore, on comparing the d2-, d22- and d24-IMes 
systems, there is an increase in both the bound T1 and free 
substrate T1 values. More importantly, when moving to 298 K 
where SABRE catalysis is conducted,(35) further increases in the 
free substrates’ protons T1 values are observed. Consequently 
we re-examined the SABRE efficiency of 2b with these catalysts 
(Table 4). Both the effective T1 relaxation times and polarization 
levels increased with the best performing catalyst,  
[IrCl(COD)(d22-IMes)] giving average polarization levels of ca. 
22.0% under 3 bar p-H2 in both methanol-d4 and ethanol-d6 
which reflects a stunning 250% improvement in the latter case.  
 
Up to this point we have conducted all SABRE catalysts under 3 
bar pressure of p-H2, which in our standard 5 mm J. Young’s Tap 
NMR tubes reflects ca. 13-fold excess with respect to the 
substrate. Thus, if p-H2 is the limiting reagent in this catalytic 
process, the reaction will ultimately progress to a point where 
normal H2 (formed by conversion of p-H2) is the dominant form 
in solution. Hence the SABRE hyperpolarization of 2b was re-
examined with [IrCl(COD)(d22-IMes)] in methanol-d4 and 
ethanol-d6 solution under 3.0-5.5 bar of p-H2 (Fig. 5). In 
methanol-d4 solution we see an increase in H-2 polarization to 
26.4% and 28.5% at 4.0 and 5.5 bar respectively. A more 
dramatic effect is observed in ethanol-d6 solution where a 55% 
increase in enhancement is observed at 5.5 bar of p-H2 when 
compared to 3.0 bar. This results in a 41.7% polarization being 
measured on the H-2 site of 2b under these conditions. These 
conditions are not used in the routine experiments we have 
described as they take the sample close to its safe pressure limit, 
and we would encourage any one repeating this work to take 
appropriate precautions.  
 
Fig. 5: Effect of p-H2 pressure on the SABRE hyperpolarization of 2b (4 eq.) 
with [IrCl(COD)(d22-IMes)] (5 mM) in methanol-d4 and ethanol-d6. 
Increasing SABRE hyperpolarization by using a co-ligand 
Our final consideration in optimizing SABRE catalysis was to 
overcome the presence of multiple copies of the agent being 
attached simultaneously to a single iridium center and thus 
diluting any polarization coming from p-H2. This would require a 
catalyst redesign, but if a co-ligand is added which cannot itself 
receive polarization a suitable test scenario can be established.  
Thus, SABRE hyperpolarization was conducted using a single 
equivalent of 2b and three equivalents of methyl-2,4,5,6-d4-
nicotinate, relative to  [IrCl(COD)(d22-IMes)] under 5.5 bar p-H2 
pressure. This led to 50% polarization being achieved in the H-2 
site of 2b, with an average of 45% across the two sites. This is a 
truly remarkable result as it is delivered after just 10 seconds of 
SABRE. Hence we believe that this strategy reflects a compelling 
route to achieve hyperpolarization which can undoubtedly be 
improved on even further through higher pressures and a 
superior catalyst.    
Solvent effect on relaxation times 
The efficiency of SABRE catalysis has been shown to be highly 
dependent on the solvent, with low hyperpolarization levels 
resulting in 100% D2O solutions despite the development of 
water soluble catalysts.(32, 33, 36, 37) We suggest that 
hyperpolarization in an ethanol-d6 solution followed by sample 
dilution to obtain a biocompatible bolus for injection reflects a 
sensible route to obtain the required signal strength for in vivo 
study. The T1 values of 2b were measured in ethanol-d6−D2O 
solvent mixtures (see supporting information). Despite the 
reduction in T1 values for the H-2 and H-5 signals of 2b in the 
mixed solvent systems, in a biocompatible mixture of 10% 
ethanol-d6 in D2O the T1 value for H-5 remains above 30 
seconds. Hence very high levels of hyperpolarization are 
expected to survive the point of injection. We have measured 
the T1 values of H-2 and H-5 in 2b in water (containing 5% D2O) 
at 9.4 T, and they fall to 6.6 and 9.3 s respectively. These values 
suggest that a detectable signal will be visible in vivo for at least 
20 s, although if these approached were to be used in 
drug/urine screening or in analytical NMR more generally there 
would be no issue with the decay of signal prior to 
measurement.   
Expanding the range of substrates 
We have also established the generality of this method by 
testing a range of additional substrates. To capture a suitable 
cross section of targets, we have employed materials bearing 
the nitrogen heterocyclic motifs, pyridazine (3), pyrimidine (4) 
and pyrazine (5) alongside isonicotinamide (6). The best 
performing isotopologues are presented in Fig. 6 and full data, 
including effective T1 relaxation times in the presence of the 
catalyst can be found in the supporting information. In all cases, 
the relaxation times and polarization levels are increased. For 
3,5-d2-pyridazine (3a), the relaxation time is increased by 550% 
and the polarization level by 1630% relative to pyridazine (3). 
Similar effects were found for pyrimidine (4), where the 
deuterated isotopologue 4a yields 4.8% polarization and a signal 
with a T1 value of over 2 minutes. Comparison of pyrazine (5) to 
2,5-d2-pyrazine (5a) shows a relaxation time increase from 32.3 
seconds to 86.2 seconds and a polarization level improvement 
from 3.3% to 11.6%. Finally, 2,5-d2-isonicotinamide (6a) gives a 
ca. 5-fold improvement in T1 and 80- and 6-fold improvements 
in polarization levels for H-3 and H-6 respectively over 6.   
These data show, therefore, that the strategy we detail to 
optimize the SABRE technology is applicable to a broad range of 
structural motifs and we suggest that most agents that have a 
need to be studied using either analytical NMR or in a clinical 
setting will benefit from isotope labelling. Table s5 in the 
supplementary information details the corresponding T1 values 
in a 95% H2O, 5% D2O solution, with 2b, 2c, 3a, 4a and 5a being 
the most likely to be detectable in vivo.  
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'Classical' SABRE conditions
[IrCl(COD)(IMes)] (5 mM), Substrate (4 eq.), 3 bar p-H2 in methanol-d4
'Optimised' SABRE using this strategy
[IrCl(COD)(d22-IMes)] (5 mM), 2H-Substrate (4 eq.), 5.5 bar p-H2 in methanol-d4  
Fig. 6: The change in T1(no cat) (in blue, seconds) and SABRE polarization (in red, 
percentage) of a range of substrates in methanol-d4 solution to illustrate the 
general benefits of 2H labelling.  SABRE conditions were: [IrCl(COD)(IMes)] (5 
mM), substrate (4 eq.), 3 bar p-H2. (IMes = 1,3-bis(2,4,6-trimethylphenyl)-
imidazol-2-ylidene) 
Assessing the impact of these changes for MRI detection 
Images of the resultant SABRE derived 1H magnetization of 1 and 
2, and their better performing deuterated analogues, have been 
collected at 9.4 T in conjunction with a 100 mM substrate 
concentration in ethanol-d6. Analogous results under reversible 
flow, where measurement-repeat is possible, are also detailed in 
the supporting information and confirm that deuteration not 
only improves the resultant image intensity relative to their 
parents but also extends the duration over which visible signals 
can be detected. The longer T1 values that these agents exhibit 
which act to inhibit standard multi-pulse-recovery observations 
are now of benefit because they should enable detection after 
in-vivo injection and transport to a region of clinical interest. 
Additionally, this change allows longer echo times to be 
employed which results in a lower duty cycle and radio 
frequency deposition rate.  
We have also been able to show that when high-contrast is 
desired, hyperpolarized signals can be observed in the presence 
of a water phantom whose signal can initially be suppressed to 
further improve the dynamic range of the image. In the cases of 
1f and 2b, the hyperpolarized agents are visible 30 seconds after 
completion of the polarization step with superior image 
intensity than that of the residual water signal. Furthermore, 
when 2b was examined after polarization transfer by 
[IrCl(COD(d22-IMes)] under 7 bar of p-H2 the corresponding 
RARE(38) images of the same samples under normal conditions 
would take 9 and 40 days of continuous averaging in ethanol-d6 
and methanol-d4 respectively to reproduce the hyperpolarized 
results (Fig. 7) that are collected less than 20 seconds after the 
start of hyperpolarization. Hence we can conclude that the MRI 
assessment of these agents without hyperpolarization would be 
impractical. We also compared these data to that obtained for 
an excised spleen and noted a 30-fold S/N improvement relative 
to the tissue’s H2O signal.  
(A) (B) (C)  
 
Fig. 7: Hyperpolarized images of methyl nicotinate using [IrCl(COD)(d22-IMes)] 
under 7 bar p-H2: (A) Control image of a tube of water; (B) SABRE 
hyperpolarized image of a sample of 2b (100 mM in methanol-d4); (C) 
analogous SABRE hyperpolarized image of a sample of 2b (100 mM in ethanol-
d6). Image SNR values are 1586, 4085 and 2955 respectively. Data were 
acquired under identical conditions and results are plotted on the same scale. 
 
Conclusions 
The results presented here suggest that placing a proton next to 
nitrogen is most desirable for efficient magnetization transfer 
via SABRE while having an isolated proton environment is 
desirable for a long signal lifetime. In the case of nicotinamide 
(1) and methyl nicotinate (2), the deuterated forms that 
hyperpolarize optimally correspond to 1f and 2b. This is because 
polarization flows from the hydride ligands in the catalyst 
through to the bound substrates receptor protons optimally 
when both their spin-spin coupling and relaxation times are 
maximized. When [IrCl(COD)(IMes)] is used as the catalyst 
precursor, 10% polarization in 2b was achieved for H-2. It has 
also been shown that the catalyst also relaxes the 
hyperpolarization it creates, an effect which can be reduced 
when it is 2H-labelled which more than doubles the level of 
delivered hyperpolarization to 22% when [IrCl(COD)(d22-IMes)] is 
employed. Increasing the p-H2 pressure from 3 to 5.5 bar further 
increases this to 41%, while 50% H-2 polarization of 2b can be 
achieved with the co-ligand methyl-2,4,5,6-d4-nicotinate.  
Given that the hyperpolarization process associated with SABRE 
is continuous,(23, 39) we predict it would be possible to 
complete any offline analyses needed to establish viability for 
future in vivo use, such as a pH assessment, prior to injection 
and the start of relaxation. Furthermore, by using the synthetic 
strategy we have described a hyperpolarized agent with ca. 50 % 
magnetic state purity (longitudinal magnetization), which is 
100,000 times bigger than the 0.0005% level of a 1.5 T hospital 
scanner, has been produced on a single spin in just a few 
seconds. The resulting hyperpolarized and slowly relaxing 
magnetization has also been harnessed productively in a series 
of MRI experiments that establish these performance 
improvements are maintained and that our optimized agents 
can deliver signals which are over one order of magnitude 
stronger than that of biological tissue. In order to harness these 
results, an automated delivery system needs to be assembled to 
enable the injection of these agents which integrates the final 
steps of sample dilution and catalyst deactivation and removal 
to ensure biocompatibility. We also expect that these levels of 
enhancement can be increased still further under conditions 
where p-H2 is no longer limiting. We are currently using this 
approach to optimally polarize 13C and 15N nuclei to extend the 
magnetization lifetimes and polarization levels of other nuclei.  
Consequently, if we were to assume that 20 seconds are 
required from the point of injection to starting an MRI 
measurement, for a nominal initial polarization level of 50% we 
would be left with ca. 7% if the T1 value was maintained at 10 
seconds in vivo. For comparison purposes, pyruvate, delivered 
with a typical 30% 13C polarization level and an in vivo T1 of 30 
seconds retains 11% polarization at this point.(40) The levels of 
polarization achieved here by SABRE is therefore fully 
commensurate with that needed for future in vivo success, 
particularly given the higher sensitivity of 1H nuclei, rather than 
13C nuclei.   
At a molecular level, we have developed and demonstrated a 
strategy to optimize the detection levels of a SABRE-
hyperpolarized biomarker. This has required the production of a 
range of 2H-labelled substrates, and the selection of their 
optimal form based on their relaxation time and SABRE 
hyperpolarization level. A combination of these procedures, with 
subsequent sample dilution, reflects a viable route to produce a 
biocompatible bolus for in vivo measurement. We are also using 
this approach to improve on low concentration NMR 
detectability for analytical purposes in a similar way. 
Furthermore, by illustrating the success of this approach for a 
variety of agents we believe that we articulate a general strategy 
to maximize both polarization amplitude and lifetime which will 
be useful to others.   
Materials and Methods 
Synthesis and Reactivity Studies All reactions utilizing air- and 
moisture-sensitive reagents were performed in dried glassware under 
an atmosphere of dry nitrogen. Dry solvents (THF, Toluene and DCM) 
were obtained from a Braun MB-SPS-800. For thin-layer 
chromatography (TLC) analysis, Merck pre-coated plates (silica gel 60 
F254, Art 5715, 0.25 mm) were used. Column chromatography was 
performed on Fluka Silica gel (60 Å, 220-440 mesh). Deuterated 
solvents (methanol-d4, ethanol-d6 and D2O) were obtained from 
Sigma-Aldrich and used as supplied. Detailed synthetic procedures 
and characterization data can be found in the supplementary 
material.  
Hyperpolarization studies 1H NMR spectra in addition to the 
relaxation data were measured on a Bruker 400 MHz spectrometer. 
SABRE hyperpolarization transfer experiments involved p-H2 that was 
produced by cooling H2 gas over Fe2O3 at 30 K. Samples contained 5 
mM concentrations of the catalyst and 5 up to 20 equivalents of 
substrate relative to iridium in the specified solvent in a 5 NMR tube 
fitted with a J. Young’s Tap. The resulting solutions were degassed 
prior to the introduction of p-H2 at a pressure of 3 bar unless 
otherwise stated. Samples were shaken for 7 seconds in a specified 
fringe field of a 9.4 T Bruker Avance (III) NMR spectrometer for 
hyperpolarization transfer prior to being rapidly transported into the 
main magnetic field of the instrument for subsequent probing by 
NMR or MRI methods. The associated polarization transfer 
experiment data can be found in the supplementary material. 
Statistical Analysis Errors have been calculated using the standard 
deviation formula, taking into account the limited number of 
population samples. Gaussian error propagation has been assumed 
(see supporting information). 
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Table 1. Hyperpolarization and T1 data for nicotinamide (1) and the seven 2H-labelled analogues 1a-1g. SABRE catalysis 
performed with 5 mM [IrCl(COD)(IMes)] (IMes = 1,3-bis(2,4,6-trimethylphenyl)-imidazol-2-ylidene), 4 equivalents of agent, 
under 3 bar p-H2 in methanol-d4 or ethanol-d6 at 298K. T1 measurements without catalyst were on a degassed sample 
containing 20 mM of agent. Errors are <5% unless otherwise specified. 
 
Agent 
Methanol-d4 Ethanol-d6 D2O 
Site 
T1(no cat.) / s 
Site 
T1(eff., with 
cat.)  /s 
Polarizatio
n Level (%) 
Site 
T1(no cat.) / s 
Site 
T1(eff., with 
cat.) /s 
Polarizatio
n Level (%) T1 / s 
1 
 
H-2: 
H-4: 
H-5: 
H-6: 
16.3 
11.3 
6.9 
9.8 
H-2: 
H-4: 
H-5: 
H-6: 
6.2 
6.3 
3.7 
3.8 
H-2: 
H-4: 
H-5: 
H-6: 
2.1 
2.0 
0.6 
1.9 
H-2: 
H-4: 
H-5: 
H-6: 
24.3 
6.7 
3.9 
7.8 
H-2: 
H-4: 
H-5: 
H-6: 
4.2 
3.9 
2.4 
2.7 
H-2: 
H-4: 
H-5: 
H-6: 
1.1 
0.8 
0.1 
1.0 
H-2: 
H-4: 
H-5: 
H-6: 
10.7 
8.9 
6.5 
7.5 
1a 
 
H-4: 
H-5: 
11.2 
11.0 
H-4: 
H-5: 
5.8 
5.8 
H-4: 
H-5: 
0.2 
0.05 
H-4: 
H-5: 
6.1 
6.2 
H-4: 
H-5: 
3.8 
3.8 
H-4: 
H-5: 
0.1 
0.0
5 
H-4: 
H-5: 
11.2 
11.3 
1b 
 
H-5: 
H-6: 
14.5 
10.9 
H-5: 
H-6: 
5.8 
3.5 
H-5: 
H-6: 
2.4 
2.4 
H-5: 
H-6: 
7.3 
6.8 
H-5: 
H-6: 
5.1 
0.5 
H-5: 
H-6: 
0.3 
0.2 
H-5: 
H-6: 
12.2 
9.5 
1c 
 
H-2: 
H-6: 
14.8 
17.0 
H-2: 
H-6: 
3.7 
0.4 
H-2: 
H-6: 
1.7 
1.3 
H-2: 
H-6: 
13.5 
16.0 
H-2: 
H-6: 
3.2 
3.4 
H-2: 
H-6: 
0.9 
0.6 
H-2: 
H-6: 
39.4 
37.9 
1d 
 
H-2: 
H-4: 
8.1 
55.8 
H-2: 
H-4: 
6.7 
25.1 
H-2: 
H-4: 
2.1 
2.4 
H-2: 
H-4: 
8.1 
30.1 
H-2: 
H-4: 
3.3 
9.3 
H-2: 
H-4: 
0.6 
0.7 
H-2: 
H-4: 
13.0 
63.5 
1e 
 
H-4: 
H-6: 
63.5 
70.4 
H-4: 
H-6: 
18.9 
2.0 
H-4: 
H-6: 
2.7 
3.2 
H-4: 
H-6: 
28.0 
28.4 
H-4: 
H-6: 
14.6 
1.9 
H-4: 
H-6: 
1.9 
1.9 
H-4: 
H-6: 
51.8 
35.2 
1f 
 
H-2: 
H-5: 
26.8 
47.9 
H-2: 
H-5: 
7.9 
20.4 
H-2: 
H-5: 
4.1 
4.1 
H-2: 
H-5: 
22.2 
37.5 
H-2: 
H-5: 
8.2 
17.5 
H-2: 
H-5: 
2.0 
2.1 
H-2: 
H-5: 
37.1 
54.0 
1g 
 
H-2: 45.7 H-2: 5.9 H-2: 2.1 H-2: 25.7 H-2: 3.8 H-2: 0.4 H-2: 28.5 
 
Table 2. Hyperpolarization and T1 data for methyl-nicotinate (2) and the four 2H-labelled analogues 2a-2d. SABRE 
catalysis performed with 5 mM [IrCl(COD)(IMes)] (IMes = 1,3-bis(2,4,6-trimethylphenyl)-imidazol-2-ylidene), 4 
equivalents of agent, under 3 bar p-H2 in methanol-d4 or ethanol-d6 at 298K. T1 measurements without catalyst 
were on a degassed sample containing 20 mM of agent. Errors are <5% unless otherwise specified.   
 
Agent 
Methanol-d4 Ethanol-d6 D2O 
Site 
T1(no cat.) /s 
Site 
T1 (eff., with 
cat.) /s 
Polarization 
Level /% 
Site 
T1(no cat.) / 
s 
Site 
T1(eff. with 
cat.) /s 
Polarization 
Level /% T1 / s 
2 
 
H-
2: 
H-
4: 
H-
5: 
H-
6: 
59.8 
22.0 
12.6 
21.4 
H-
2: 
H-
4: 
H-
5: 
H-
6: 
4.9 
6.5 
3.6 
3.1 
H-2: 
H-4: 
H-5: 
H-6: 
3.7 
3.1 
1.3 
3.0 
H-
2: 
H-
4: 
H-
5: 
H-
6: 
48.9
14.4
8.1 
14.1 
H-
2: 
H-
4: 
H-
5: 
H-
6: 
8.0 
5.2 
4.9 
8.7 
H-2: 
H-4: 
H-5: 
H-6: 
2.6 
1.7 
0.7 
1.9 
H-
2: 
H-
4: 
H-
5: 
H-
6: 
13.8
8.3 
6.2 
8.7 
2a 
 
H-
2: 
H-
4: 
H-
5: 
H-
6: 
67.2 
22.3 
12.4 
21.0 
H-
2: 
H-
4: 
H-
5: 
H-
6: 
5.3 
3.1 
7.0 
3.1 
H-2: 
H-4: 
H-5: 
H-6: 
5.8 
5.3 
1.4 
4.1 
H-
2: 
H-
4: 
H-
5: 
H-
6: 
31.0
13.9
7.9 
12.3 
H-
2: 
H-
4: 
H-
5: 
H-
6: 
14.9
8.3 
4.9 
5.1 
H-2: 
H-4: 
H-5: 
H-6: 
1.5 
1.1 
0.5 
1.1 
H-
2: 
H-
4: 
H-
5: 
H-
6: 
37.1
8.9 
6.8 
12.2 
2b 
 
H-
2: 
H-
5: 
65.7 
97.6 
H-
2: 
H-
5: 
5.8 
20.9 
H-2: 
H-5: 
10.1 
9.5 
H-
2: 
H-
5: 
46.2
62.7 
H-
2: 
H-
5: 
6.8 
18.8 
H-2: 
H-5: 
9.3 
8.2 
H-
2: 
H-
5: 
30.9
47.4 
S9 
 
2c 
 
H-
2: 
H-
5: 
116.0 
107 
H-
2: 
H-
5: 
6.6 
23.8 
H-2: 
H-5: 
9.5 
8.3 
H-
2: 
H-
5: 
49.8
66.3 
H-
2: 
H-
5: 
5.5 
15.6 
H-2: 
H-5: 
7.5 
7.0 
H-
2: 
H-
5: 
50.1
50.3 
2d 
 
H-
5: 
H-
6: 
26.0 
20.6 
H-
5: 
H-
6: 
5.5 
4.7 
H-5: 
H-6: 
3.7 
4.0 
H-
5: 
H-
6: 
16.7
14.6 
H-
5: 
H-
6: 
5.5 
3.6 
H-5: 
H-6: 
2.7 
2.9 
H-
5: 
H-
6: 
15.7
14.2 
2e 
 
H-
4: 
H-
6: 
94.3 
64.4 
H-
4: 
H-
6: 
28.2
6.8 
H-4: 
H-6: 
11.0 
9.5 
H-
4: 
H-
6: 
61.2
47.9 
H-
4: 
H-
6: 
24.6
9.2 
H-4: 
H-6: 
6.2 
6.1 
H-
4: 
H-
6: 
44.2
48.8 
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Table 3: Effective T1 values for protons H-2 and H-5 in methyl-4,6-d2-nicotinate 2b (20mM loading), and the corresponding 
equatorial and axial ligands of the SABRE catalyst with [IrCl(COD)(NHC)] (where NHC = IMes, d2-, d22- or d24-IMes, at 5 mM 
loading) and H2 or D2 ( 3 bar) in methanol-d4 solution at 263 K. 
NHC IMes T1(eff., with cat.) /s 
d2-IMes 
T1(eff., with cat.) /s 
d22-IMes 
T1(eff., with cat.) /s 
d24-IMes 
T1(eff., with cat.) /s 
Gas H2 D2 H2 D2 H2 D2 H2 D2 
2b 
H-
2: 
H-
5: 
10.6 
18.4 
H-
2: 
H-
5: 
10.9 
18.3 
H-
2: 
H-
5: 
13.1
20.3 
H-
2: 
H-
5: 
13.8
25.3 
H-
2: 
H-
5: 
13.5
23.2 
H-
2: 
H-
5: 
20.1
23.7 
H-
2: 
H-
5: 
12.1 
21.0 
H-
2: 
H-
5: 
14.1
30.9 
Equatorially 
Bound 2b 
H-
2: 
H-
5: 
1.4 
6.7 
H-
2: 
H-
5: 
1.9 
5.6 
H-
2: 
H-
5: 
2.0 
6.7 
H-
2: 
H-
5: 
1.5 
6.5 
H-
2: 
H-
5: 
2.0 
9.0 
H-
2: 
H-
5: 
2.6 
7.3 
H-
2: 
H-
5: 
3.2 
12.0 
H-
2: 
H-
5: 
2.3 
10.5 
Axially 
Bound 2b 
H-
2: 
H-
5: 
1.9 
2.3 
H-
2: 
H-
5: 
4.1 
2.4 
H-
2: 
H-
5: 
1.7 
4.0 
H-
2: 
H-
5: 
3.6 
2.7 
H-
2: 
H-
5: 
2.5 
8.0 
H-
2: 
H-
5: 
4.8 
3.8 
H-
2: 
H-
5: 
1.7 
12.3 
H-
2: 
H-
5: 
4.0 
10.1 
 
Table 4: Effect of 2H-labelling the catalyst on the effective T1 values and polarization levels of H-2 and H-5 in 2b 
under SABRE catalysis by [IrCl(COD)(NHC)] (where NHC = d2-, d22- or d24-IMes) with 3 bar p-H2 at 298 K. 
NHC 
Methanol-d4 Ethanol-d6 
T1(eff., with cat.) /s Polarization /% T1(eff., with cat.) /s Polarization /% 
d2-IMes 
H-2: 
H-5: 
5.8 
20.9 
H-2: 
H-5: 
10.1 
9.5 
H-2: 
H-5: 
5.5 
15.6 
H-2: 
H-5: 
9.3 
8.2 
d22-IMes 
H-2: 
H-5: 
7.7 
26.6 
H-2: 
H-5: 
24.1 
19.9 
H-2: 
H-5: 
7.7 
17.2 
H-2: 
H-5: 
26.8 
16.6 
d24-IMes 
H-2: 
H-5: 
9.5 
33.5 
H-2: 
H-5: 
18.6 
16.5 
H-2: 
H-5: 
7.5 
19.3 
H-2: 
H-5: 
13.3 
8.2 
 
  
S11 
 
Delivering  Strong 1H Nuclei Hyperpolarization Levels and Long 
Magnetic Lifetimes through Signal Amplification by Reversible 
Exchange 
Peter J. Rayner, Michael  J. Burns, Alexandra M. Olaru, Philip Norcott, Marianna Fekete, Gary 
G. R. Green, Louise A. R. Highton, Ryan. E. Mewis and Simon. B. Duckett* 
Centre for Hyperpolarisation in Magnetic Resonance, Department of Chemistry, University of York, 
Heslington, YO10 5NY  
 
1. Synthesis and characterisation 
 1.1  General 
 1.2  General Procedures 
 1.3 Synthetic procedures and characterisation data 
2. NMR experiments 
 2.1  Polarization transfer methods 
2.2  1H Enhancement factors calculation and statistical analysis 
2.3 Representative NMR spectra of the SABRE effect in deuterated agents 
2.4 Polarisation transfer with deuterated IMes catalysts 
2.5  Effect of pH2 pressure on polarisation with [IrCl(COD)(d22-IMes)] 
2.6 Use of methyl-2,4,5,6-d4-nicotinate as a co-substrate 
2.7  Kinetic behaviour of 2b with [IrCl(COD)(NHC)] under H2 
2.8  T1 relaxation data for 2b in ethanol-d6:D2O solvent mixtures 
2.9  T1 relaxation data in H2O solution containing 5% D2O 
 
3. SABRE MRI Collection 
3.2 MRI Instrumentation and Procedures 
3.2.1 MRI instrumentation 
3.2.2 MRI acquisition methods 
3.2.3 MRI data processing and statistical analysis 
3.3 Results 
3.3.1 Image intensity optimisation through selective deuteration 
3.3.2 Effects of relaxation on image quality 
3.3.3 Image contrast optimisation by water and solvent suppression 
3.3.4   Effects of pH2 pressure on image quality 
 
 
S12 
 
1. Synthesis and characterisation 
1.1 General 
Water is distilled water. Brine refers to a saturated aqueous solution of NaCl. THF was 
freshly distilled from sodium and benzophenone ketyl or dried using a Grubbs solvent 
purification system. Petrol refers to the fraction of petroleum ether boiling in the range 40-
60 °C. All reactions were carried out under O2-free Ar or N2 using oven-dried and/or flame-
dried glassware.   
 
Flash column chromatography was carried out using Fluka Chemie GmbH silica (220-440 
mesh). Reverse-phase flash column chromatography was carried out using a Biotage Isolera 
with a SNAP-C18-12g cartridge eluting with H2O-MeCN containing 0.1% NH4OH.  Thin layer 
chromatography was carried out using Merck F254 aluminium-backed silica plates. 1H (400 
MHz) and 13C (100.6 MHz) NMR spectra were recorded on a Bruker-400 instrument with an 
internal deuterium lock. Chemical shifts are quoted as parts per million and referenced to 
CHCl3 (δH 7.27), (CH3)2SO (δH 2.54), CDCl3 (δC 77.0) or (CD3)2SO (δC 40.45). 13C NMR spectra 
were recorded with broadband proton decoupling. 13C NMR spectra were assigned using 
DEPT experiments where necessary. Coupling constants (J) are quoted in Hertz. Electrospray 
high and low resolution mass spectra were recorded on a Bruker Daltonics microOTOF 
spectrometer.   
 
All compounds were purchased from Sigma-Aldrich, Fluorochem or Alfa-Aesar and used as 
supplied unless otherwise stated.  The following compounds were synthesised according to 
literature procedures; methyl-2,4-dichloronicotinate,(1) ethyl-4,5,6-trichloronicotinate,(2) 
and [IrCl(COD)(IMes)].(3)  
 
1.2 General Procedures 
General Procedure A – Deuteration of heteroaryl chlorides 
5% Pd/C (10 wt%) was added to a stirred suspension of heteroaryl chloride (1.0 eq.) and 
K2CO3 (2.5 - 3.5 eq.) in MeOD (10 mL) or EtOD (10 mL) in a 30 mL Parr Reactor.  The Parr 
reactor was sealed, purged with N2(g) and pressurised with D2(g) (5 bar).  The reaction was 
then stirred at rt for 3 h.  Then, the pressure was released and the suspension was filtered 
through Celite® and washed with CH2Cl2.  The filtrate was concentrated under reduced 
pressure to give the crude product. 
 
General Procedure B – Synthesis of nicotinamide by amide formation 
The nicotinate (1.0 eq) was dissolved in ammonia (10 mL of a 7 N solution in MeOH) and the 
resulting solution stirred at rt for 2 days.  The solution was concentrated under reduced 
pressure to give the crude product. 
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1.3 Synthetic procedures and characterisation data 
Methyl-2,6-d2-nicotinate S1 
 
Using General Procedure A, methyl-2,6-dichloronicotinate (100 mg, 0.485 mmol, 1.0 eq.), 
5% Pd/C (10 mg, 10 wt%), K2CO3 (167 mg, 1.21 mmol, 2.5 eq.) and D2(g) (5 bar) in THF (10 
mL) gave the crude product.  Purification by flash column chromatography with 1:1 petrol-
EtOAc as eluent gave methyl-2,6-d2-nicotinate S1 (43 mg, 63%) as a pale yellow solid, RF (1:1 
petrol-EtOAc) 0.3; 1H NMR (400 MHz, CDCl3) δ (ppm) 8.30 (d, J = 8.1 Hz, 1H), 7.40 (d, J = 8.1 
Hz, 1H), 3.96 (s, 3H); 13C NMR (101 MHz, CDCl3) δ (ppm) 165.8 (s), 153.1 (t, J = 28.1 Hz), 
150.5 (t, J = 28.1 Hz), 137.1 (s), 125.9 (s), 123.2 (s), 52.4 (s); MS (ESI) m/z 140 [(M + H)+, 100]; 
HRMS (ESI) m/z [M + H]+ calculated for C7H6D2NO2 140.0675, found 140.0674 (−1.8 ppm 
error). 
2,6-d2-Nicotinamide 1a 
 
Using General Procedure B, methyl-2,6-d2-nicotinate S1 (45 mg, 0.324 mmol) in ammonia (6 
mL of a 7 N  solution in MeOH) gave the crude product.  Purification by reverse phase flash 
column chromatography (0-30% MeCN) gave 2,6-d2-nicotinamide 1a (34 mg, 85%) as a 
white solid, 1H NMR (400 MHz, d6-DMSO) δ (ppm) 8.22 (d, J = 8.0 Hz, 1H), 8.21 (br s, 1H), 
7.62 (br s, 1H) 7.50 (d, J = 8.0 Hz, 1H); 13C NMR (101 MHz, d6-DMSO) δ (ppm) 166.9 (s), 152.0 
(t, J = 26.5 Hz), 148.8 (t, J = 27.0 Hz), 135.7 (s), 130.0 (s), 123.8 (s); MS (ESI) m/z 147 [(M + 
Na)+, 72]  125 [(M + H)+, 100]; HRMS (ESI) m/z [M + H]+ calculated for C6H5D2N2O 125.0678, 
found 125.0679 (−0.7 ppm error). 
Ethyl-2,4-d2-nicotinate S2 
 
Using General Procedure A, methyl-2,4-dichloronicotinate(1) (135 mg, 0.65 mmol, 1.0 eq.), 
5% Pd/C (14 mg, 10 wt%), K2CO3 (250 mg, 2.75 mmol, 2.5 eq.) and D2(g) (5 bar) in EtOD (10 
mL) gave the crude product.  Purification by flash column chromatography with 1:1 petrol-
EtOAc as eluent gave ethyl-2,4-d2-nicotinate S2 (62 mg, 62%) as a pale yellow oil, RF (1:1 
petrol-EtOAc) 0.3; 1H NMR (400 MHz, CDCl3) δ (ppm) 8.77-8.75 (m, 1H), 7.38-7.37 (m, 1H), 
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4.41 (qd, J = 7.2, 3.3 Hz, 2H), 1.42-1.38 (m, 3H); 13C NMR (101 MHz, CDCl3) δ (ppm) 165.2 (s), 
153.3 (s), 150.5 (t, J = 28.1 Hz), 136.7 (t, J = 25.1 Hz), 126.1 (s), 123.1 (s), 61.4 (s), 14.2 (s); MS 
(ESI) m/z 154 [(M + H)+, 100],  126 [32]; HRMS (ESI) m/z [M + H]+ calculated for C8H8D2NO2 
154.0832, found 154.0831 (+1.4 ppm error). 
2,4-d2-Nicotinamide 1b 
 
Using General Procedure B, ethyl 2,4-d2-nicotinate S2 (62 mg, 0.406 mmol) in ammonia (5 
mL of a 7 N  solution in MeOH) gave the crude product.  Purification by reverse phase flash 
column chromatography (0-30% MeCN) gave 2,4-d2-nicotinamide 1b (50 mg, 100%) as a 
white solid, 1H NMR (400 MHz, d6-DMSO) δ (ppm) 8.70 (d, J = 4.6 Hz, 1H), 8.18 (br s, 1H), 
7.62 (br s, 1H), 7.50 (d, J = 4.6 Hz, 1H); 13C NMR (101 MHz, d6-DMSO) δ (ppm) 166.9 (s), 
152.4 (s), 148.8 (t, J = 27.1 Hz), 135.3 (t, J = 26.4 Hz), 129.9 (s), 123.8 (s); MS (ESI) m/z 147 
[(M + Na)+, 45], 125 [(M + H)+, 100]; HRMS (ESI) m/z [M + H]+ calculated for C6H5D2N2O 
125.0678, found 125.0681 (−1.8 ppm error). 
 
3-Bromo-2,4,5,6-d4-pyridine N-oxide S3 
 
A solution of 3-bromopyridine N-oxide (1.07 g, 6.15 mmol), NaOH (100 mg, 2.5 mmol, 0.4 
eq.) and D2O (10 mL) was heated to 180 °C in a microwave for 1 h. The reaction was 
concentrated under reduced pressure and refreshed with D2O (10 mL), then heated to 180 
°C for a further hour in a microwave. The solvent was removed under reduced pressure and 
the process repeated an additional time. The reaction was subsequently concentrated under 
reduced pressure and dissolved in CH2Cl2 (50 mL), dried over MgSO4(s), filtered and 
concentrated under reduced pressure to afford 3-bromo-2,4,5,6-d4-pyridine N-oxide S3 
(1.05 g, 96%) as a pale yellow oil which was used without further purification, 13C NMR (126 
MHz, CDCl3) δ (ppm) 140.7  (t, J = 29.3 Hz), 137.8 (t, J = 29.0 Hz), 128.4 (t, J = 26.6 Hz), 125.6 
(t, J = 25.7 Hz), 120.4 (s); MS (ESI) m/z 202 [(81Br-M + Na)+, 70], 200 [(79Br-M + Na)+, 72], 180 
[(81Br-M + H)+, 96], 178 [(79Br-M + H)+, 100]; HRMS (ESI) m/z [M + H]+ calculated for 
C5H79BrD4NO 177.9800, found 177.9805 (−1.4 ppm error). 
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3-Bromo-4,5-d2-pyridine N-oxide S4 
 
A solution of 3-bromo-2,4,5,6-d4-pyridine N-oxide S3 (400 mg, 2.25 mmol), K2CO3 (200 mg, 
1.45 mmol, 0.65 eq.) and H2O (20 mL) was heated to 100 °C for 16 h. The reaction was 
concentrated under reduced pressure and dissolved in CH2Cl2 (50 mL), dried over MgSO4(s), 
filtered and concentrated under reduced pressure to afford  3-bromo-4,5-d2-pyridine N-
oxide S4 (334 mg, 84%) as a pale yellow oil used without further purification, 1H NMR (400 
MHz, CDCl3) δ (ppm) 8.35 (s, 1H), 8.14 (s, 1H), 7.40 (s, 0.12 H), 7.16 (d, J = 6.0 Hz, 0.06 H); 13C 
NMR (101 MHz, CDCl3) δ (ppm) 140.9  (s), 138.1 (s), 128.4 (t, J = 26.8 Hz), 125.8 (t, J = 25.7 
Hz), 120.5 (s); MS (ESI) m/z 200 [(81Br-M + Na)+, 98], 198 [(79Br-M + Na)+, 100], 178 [(81Br-M 
+ H)+, 71], 176 [(79Br-M + H)+, 70]; HRMS (ESI) m/z [M + H]+ calculated for C5H379BrD2NO 
175.9675, found 175.9670 (+3.9 ppm error). 
 
Methyl 4,5-d2-nicotinate N-oxide S5 
 
A solution of 3-bromo-4,5-d2-pyridine N-oxide S4 (180 mg, 1.02 mmol), Et3N (1 mL, 13.6 
mmol, 13.3 eq.), PdCl2(dppf) (20 mg, 0.025 mmol, 2.5 mol%) and MeOH (10 mL) was heated 
to 75 °C under CO(g) (4 Bar) for 4 h. The reaction was allowed to cool and concentrated 
under reduced pressure to afford the crude product. Purification by flash column 
chromatography (0-10% MeOH in CH2Cl2) gave methyl-4,5-d2-nicotinate N-oxide S5 (124 mg, 
78%) as a pale yellow waxy solid, RF (95:5 CH2Cl2-MeOH) 0.3; 1H NMR (400 MHz, CDCl3) δ 
(ppm) 8.53 (s, 1H), 8.46 (s, 1H), 7.80 (s, 0.11H), 7.58 (s, 0.05H), 3.89 (s, 3H); 13C NMR (101 
MHz, CDCl3) δ (ppm) 163.7 (s), 142.9 (s), 139.3 (s), 129.8 (s), 127.0 (t, J = 25.5 Hz), 125.5 (t, J 
= 26.3 Hz), 53.4 (s); MS (ESI) m/z 178 [(M + Na)+, 50], 156 [(M + H)+, 50]; HRMS (ESI) m/z [M 
+ H]+ calculated for C7H6D2NO3 156.0624, found 156.0619 (+2.2 ppm error). 
 
Methyl 4,5-d2-nicotinate S6 
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To a solution of methyl 4,5-d2-nicotinate N-oxide S5 (240 mg, 1.36 mmol) and CH2Cl2 (8 mL) 
was added PCl3 (0.8 mL) and the reaction  heated to 40 °C for 2 h. The reaction was allowed 
to cool and quenched by careful addition onto ice. The resulting solution was adjusted to pH 
> 7 by addition of NaHCO3(s) and extracted with CH2Cl2 (3 × 50 mL). The combined extracts 
were concentrated under reduced pressure to afford the crude product. Purification by flash 
column chromatography (1:1 hexane-EtOAc) gave methyl 4,5-d2-nicotinate S6 (128 mg, 
59%) as a pale yellow waxy solid, RF (1:1 hexane-EtOAc) 0.3; 1H NMR (400 MHz, CDCl3) δ 
(ppm) 9.24 (s, 1H), 8.79 (s, 1H), 8.30 (s, 0.11H), 7.40 (d, J = 4.1 Hz, 0.06 Hz), 3.97 (s, 3H); 13C 
NMR (101 MHz, CDCl3) δ (ppm) 165.8 (s), 153.4 (s), 150.9 (S), 136.6 (t, J = 26.2 Hz), 125.9 (s), 
122.9 (t, J = 25.8 Hz), 52.4 (s); MS (ESI) m/z 154 [(M + H)+, 100]; HRMS (ESI) m/z [M + H]+ 
calculated for C7H6D2NO2 140.0675, found 140.0670 (+3.6 ppm error). 
 
4,5-d2-Nicotinamide 1c 
 
Using General Procedure B, methyl-4,5-d2-nicotinate S6 (104 mg, 0.751 mmol) in ammonia 
(5 mL of a 7 N  solution in MeOH) gave the crude product.  Purification by reverse phase 
flash column chromatography (0-30% MeCN) gave 4,5-d2-nicotinamide 1c (62 mg, 67%) as a 
white solid, 1H NMR (400 MHz, d6-DMSO) δ (ppm) 9.04 (s, 1H), 8.71 (s, 1H), 8.21 (s, 0.11H), 
8.16 (br s, 1H), 7.60 (br s, 1H), 7.50 (d, J = 4.7 Hz, 0.06 Hz); 13C NMR (101 MHz, d6-DMSO) δ 
(ppm) 166.9 (s), 152.3 (s), 149.1 (s), 135.2 (t, J = 25.2 Hz), 130.0 (s), 123.5 (t, J = 24.9 Hz); MS 
(ESI) m/z 147 [(M + Na)+, 100],  125 [(M + H)+, 83]; HRMS (ESI) m/z [M + H]+ calculated for 
C6H5D2N2O 125.0678, found 125.0677 (+1.0 ppm error). 
 
Ethyl 5,6-d2-nicotinate S7 
 
Using General Procedure A, methyl 5,6-dichloronicotinate (160 mg, 0.776 mmol, 1.0 eq.), 
5% Pd/C (30 mg, 20 wt%), K2CO3 (200 mg, 1.45 mmol, 1.9 eq.) and D2(g) (5 bar) in EtOD (10 
mL) gave the crude product.  Purification by flash column chromatography with 1:1 hexane-
EtOAc as eluent gave ethyl 5,6-d2-nicotinate S7 (119 mg, 99%) as a pale yellow solid, RF (1:1 
hexane-EtOAc) 0.3; 1H NMR (400 MHz, CDCl3) δ (ppm) 9.24 (d, J = 2.0 Hz, 1H), 8.31 (br. s, 
1H), 4.43 (q, J = 7.1, 2H), 1.43 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ (ppm) 165.3 (s), 
152.9 (t, J = 26.4 Hz), 150.9 (s), 136.9 (s), 126.3 (s), 122.8 (t, J = 24.7 Hz), 61.5 (s), 14.3 (s); 
MS (ESI) m/z 154 [(M + H)+, 100], 126 [25]; HRMS (ESI) m/z [M + H]+ calculated for C8H8-
D2NO2 154.0832, found 154.0837 (‒3.0 ppm error). 
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5,6-d2-Nicotinamide 1d 
 
Using General Procedure B, ethyl-5,6-d2-nicotinate S7 (119 mg, 0.776 mmol) in ammonia (5 
mL of a 7 N  solution in MeOH) gave the crude product.  Purification by reverse phase flash 
column chromatography (0-30% MeCN) gave 5,6-d2-nicotinamide 1d (96 mg, 99%) as a 
white solid, 1H NMR (400 MHz, d6-DMSO) δ (ppm) 9.04 (d, J = 2.3 Hz, 1H), 8.22 (d, J = 2.3 Hz, 
1H), 8.19 (br s, 1H), 7.61 (br s, 1H); 13C NMR (101 MHz, d6-DMSO) δ (ppm) 166.9 (s), 152.0 (t, 
J = 27.3 Hz), 149.1 (s), 135.5 (s), 130.1, 123.5 (t, J = 24.9 Hz); MS (ESI) m/z 147 [(M + Na)+, 
95],  125 [(M + H)+, 100]; HRMS (ESI) m/z [M + H]+ calculated for C6H5D2N2O 125.0678, found 
125.0679 (−0.3 ppm error). 
 
5-Bromo-2-chloronicotinamide S8 
 
A solution of methyl 5-bromo-2-chloronicotinate (250 mg, 1 mmol) was dissolved in 
ammonia (5  mL of a 7 N solution in MeOH) and the resulting solution stirred at rt for 16 h. 
Concentration under reduced pressure afforded 5-bromo-2-chloronicotinamide S8 (235 mg, 
100%) as a crystalline white solid, used without further purification. 1H NMR (500 MHz, d6-
DMSO) δ (ppm) 8.64 (s, 1H), 8.22 (s, 1H), 8.12 (br. S, 1H), 7.88 (br.s, 1H); 13C NMR (126 MHz, 
d6-DMSO) δ (ppm) 165.8 (s), 151.0 (s), 145.8 (s), 140.4 (s), 135.0 (s), 119.3 (s); MS (ESI) m/z 
239 [(81Br /37Cl-M + H)+, 30] , 237 [(81Br /35Cl-M + H)+, (79Br /37Cl-M + H)+, 100], 235 [(79Br 
/35Cl-M + H)+,80]. 
 
Methyl-2,5-d2-nicotinate 1e 
 
Using General Procedure A, 5-bromo-2-chloronicotinamide S8 (100 mg, 0.425 mmol, 1.0 
eq.), 5% Pd/C (20 mg, 20 wt%), K2CO3 (150 mg, 1.09 mmol, 2.5 eq.) and D2(g) (7 bar) in EtOD 
(10 mL) gave the crude product.  Purification by reverse phase flash column 
chromatography (0-30% MeCN) gave 2,5-d2-nicotinamide 1e (46 mg, 87%) as a white solid, 
1H NMR (400 MHz, d6-DMSO) δ (ppm) 8.7 (d, J = 1.5 Hz, 1H), 8.21 (d, J = 1.5 Hz, 1H), 8.19 (br 
s, 1H), 7.61 (br s, 1H); 13C NMR (101 MHz, d6-DMSO) δ (ppm) 166.9 (s), 152.3 (s), 148.8 (t, J = 
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26.9 Hz), 135.5 (s), 130.0 (s), 123.6 (t, J = 23.1 Hz); MS (ESI) m/z 125 [(M + H)+, 100]; HRMS 
(ESI) m/z [M + H]+ calculated for C6H5D2N2O 125.0678, found 125.0685 (−4.9 ppm error). 
 
Methyl 4,6-d2-nicotinate 2b 
 
5% Pd/C (50 mg, 10 wt%) was added to a stirred suspension of 4,6-dichloronicotinic acid 
(500 mg, 2.63 mmol, 1.0 eq.) and K2CO3 (910 mg, 6.58 mmol, 2.5 eq.) in a 1:1 mix of THF-
D2O (14 mL) in a 30 mL Parr Reactor.  The Parr reactor was sealed, purged with N2(g) and 
pressurised with D2(g) (8 bar).  The reaction was stirred at rt for 16h.  Then, the pressure was 
released and the suspension was filtered through Celite® and washed with CH2Cl2 (3 x 15 
mL).  The filtrate was concentrated under reduced pressure to give a solid residue that was 
dissolved in CH2Cl2 (10 mL).  Then, oxalyl chloride (265 µL, 3.16 mmol, 1.2 eq.) and DMF (2 
drops) were added and the resulting solution was stirred at rt for 1 h.  The reaction was 
concentrated under reduced pressure and CH2Cl2 (10 mL), Et3N (857 µL, 6.58 mmol, 2.5 eq.) 
and MeOH (1.0 mL) were added sequentially.  The resulting solution was stirred at rt for 10 
min. The aqueous layer was extracted with CH2Cl2 (2 x 10 mL).  The combined organic layers 
were dried (MgSO4) and concentrated under reduced pressure to give the crude product.  
Purification by flash column chromatography with 1:1 petrol-EtOAc as eluent gave methyl-
4,6-d2-nicotinate 2b (318 mg, 78%) as a pale yellow solid, RF (1:1 petrol-EtOAc) 0.3; 1H NMR 
(400 MHz, CDCl3) δ (ppm) 9.18 (s, 1H), 7.36 (s, 1H), 3.92 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 
(ppm) 165.7 (s), 153.0 (t, J = 27.4 Hz), 150.8 (s), 136.8 (t, J = 25.4 Hz), 125.9 (s), 123.0 (s), 
52.4 (s); MS (ESI) m/z 140 [(M + H)+, 100]; HRMS (ESI) m/z [M + H]+ calculated for C7H6D2NO2 
140.0675, found 140.0673 (+1.5 ppm error). 
 
4,6-d2-Nicotinamide 1f 
 
Using General Procedure B, methyl-4,6-d2-nicotinate 2b (200 mg, 1.31 mmol) in ammonia 
(10 mL of a 7 N  solution in MeOH) gave the crude product.  Purification by reverse phase 
flash column chromatography (0-30% MeCN) gave 4,6-d2-nicotinamide 1f (144 mg, 89%) as 
a white solid, 1H NMR (400 MHz, d6-DMSO) δ (ppm) 9.03 (s, 1H), 8.19 (br s, 1H), 7.63 (br s, 
1H), 7.50 (s, 1H); 13C NMR (101 MHz, d6-DMSO) δ (ppm) 166.9 (s), 152.0 (t, J = 27.5 Hz), 
149.1 (s), 135.3 (t, J = 24.9 Hz), 130.0 (s), 123.6 (s); MS (ESI) m/z 147 [(M + Na)+, 55],  125 [(M 
+ H)+, 100]; HRMS (ESI) m/z [M + H]+ calculated for C6H5D2N2O 125.0678, found 125.0681 
(−1.8 ppm error). 
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Ethyl 4,5,6-d3-nicotinate S9 
 
Using General Procedure A, ethyl-4,5,6-trichloronicotinate(2) (150 mg, 0.60 mmol, 1.0 eq.), 
5% Pd/C (15 mg, 10 wt%), K2CO3 (207 mg, 2.10 mmol, 3.5 eq.) and D2(g) (5 bar) in EtOD (10 
mL) gave the crude product.  Purification by flash column chromatography with 1:1 petrol-
EtOAc as eluent gave ethyl-4,5,6-d3-nicotinate S9 (68 mg, 75%) as a pale yellow solid, RF (1:1 
petrol-EtOAc) 0.3; 1H NMR (400 MHz, CDCl3) δ (ppm) 9.24 (s, 1H), 4.41 (q, J = 8.0 Hz, 2H), 
1.43 (t, J = 8.0 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ (ppm) 165.3 (s), 152.9 (t, J = 26.6 Hz), 
150.9 (s), 136.6 (t, J = 25.4 Hz), 126.3 (s), 122.7 (t, J = 25.4 Hz), 61.4 (s), 14.3 (s); MS (ESI) m/z 
177 [(M + Na)+, 100],  155 [(M + H)+, 50]; HRMS (ESI) m/z [M + H]+ calculated for C8H6D3NO2 
177.0719, found 177.0719 (−0.1 ppm error). 
 
4,5,6-d3-Nicotinamide 1g 
 
Using General Procedure B, ethyl-4,5,6-d3-nicotinate S9 (60 mg, 0.39 mmol) in ammonia (10 
mL of a 7 N solution in MeOH) gave the crude product.  Purification by reverse phase flash 
column chromatography (0-30% MeCN) gave 4,5,6-d3-nicotinamide 1g (39 mg, 94%) as a 
white solid, 1H NMR (400 MHz, d6-DMSO) δ (ppm) 9.04 (s, 1H), 8.17 (br s, 1H), 7.60 (br s, 
1H); 13C NMR (101 MHz, d6-DMSO) δ (ppm) 166.9 (s), 152.0 (t, J = 27.7 Hz), 149.2 (s), 135.2 
(t, J = 25.6 Hz), 130.0 (s), 123.3 (t, J = 25.6 Hz); MS (ESI) m/z 148 [(M + Na)+, 50],  126 [(M + 
H)+, 100]; HRMS (ESI) m/z [M + H]+ calculated for C6H4D3N2O 126.0741, found 126.0744 
(−1.9 ppm error). 
 
d3-Methyl nicotinate 2a 
 
CD3OD (2.0 mL) was added to a stirred solution of nicotinoyl chloride hydrochloride (534 
mg, 3.0 mmol, 1.0 eq.) and Et3N (1.04 mL, 7.5 mmol, 2.5 eq.) in CH2Cl2 (10 mL) at rt under 
N2.  The resulting solution was stirred at rt for 10 min.  Then, a saturated solution of 
NaHCO3(aq) (20 mL) was added and the two layers were separated.  The aqueous layer was 
extracted with CH2Cl2 (2 x 10 mL).  The combined organic layers were dried (MgSO4) and 
concentrated under reduced pressure to give the crude product.  Purification by flash 
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column chromatography with 1:1 petrol-EtOAc as eluent gave d3-methyl nicotinate 2a (320 
mg, 78%) as a pale yellow solid, RF (1:1 petrol-EtOAc) 0.3; 1H NMR (400 MHz, CDCl3) δ (ppm) 
9.18 (dd, J = 2.1, 0.8 Hz, 1H), 8.73 (dd, J = 4.9, 1.7 Hz, 1H), (ddd, J = 7.9, 2.1, 1.7 Hz, 1H), 7.35 
(ddd, J = 7.9, 4.9, 0.8 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ (ppm) 165.7 (s), 153.4 (s), 150.9 
(s), 137.0 (s), 126.0 (s), 123.2 (s), 51.6 (sept., J = 22.5 Hz); MS (ESI) m/z 141 [(M + H)+, 100]; 
HRMS (ESI) m/z [M + H]+ calculated for C7H5D3NO2 141.0738, found 141.0736 (+1.2 ppm 
error). 
 
d3-Methyl-4,6-d2-nicotinate 2c 
 
5% Pd/C (50 mg, 10 wt%) was added to a stirred suspension of 4,6-dichloronicotinic acid 
(500 mg, 2.63 mmol, 1.0 eq.) and K2CO3 (910 mg, 6.58 mmol, 2.5 eq.) in a 1:1 mix of THF-
D2O (14 mL) in a 30 mL Parr Reactor.  The Parr reactor was sealed, purged with N2(g) and 
pressurised with D2(g) (8 bar).  The reaction was stirred at rt for 16h.  Then, the pressure was 
released and the suspension was filtered through Celite® and washed with CH2Cl2 (3 x 15 
mL).  The filtrate was concentrated under reduced pressure to give a solid residue that was 
dissolved in CH2Cl2 (10 mL).  Then, oxaloyl chloride (265 µL, 3.16 mmol, 1.2 eq.) and DMF (2 
drops) were added and the resulting solution was stirred at rt for 1 h.  The reaction was 
concentrated under reduced pressure and CH2Cl2 (10 mL), Et3N (857 µL, 6.58 mmol, 2.5 eq.) 
and CD3OD (1.0 mL) were added sequentially.  The resulting solution was stirred at rt for 10 
min. The aqueous layer was extracted with CH2Cl2 (2 x 10 mL).  The combined organic layers 
were dried (MgSO4) and concentrated under reduced pressure to give the crude product.  
Purification by flash column chromatography with 1:1 petrol-EtOAc as eluent gave d3-
methyl-4,6-d2-nicotinate 2a (333 mg, 91%) as a pale yellow solid, RF (1:1 petrol-EtOAc) 0.3; 
1H NMR (400 MHz, CDCl3) δ (ppm) 9.16 (s, 1H), 7.34 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 
(ppm) 165.7 (s), 153.0 (t, J = 27.4 Hz), 150.8 (s), 136.7 (t, J = 25.4 Hz), 125.9 (s), 123.0 (s), 
51.6 (sept., J = 22.6 Hz); MS (ESI) m/z 143 [(M + H)+, 100]; HRMS (ESI) m/z [M + H]+ 
calculated for C7H3D5NO2 143.0863, found 143.0858 (+3.2 ppm error). 
 
Methyl-2,4-d2-nicotinate 2d 
 
5% Pd/C (50 mg, 10 wt%) was added to a stirred suspension of 2,5-dichloronicotinic acid 
(500 mg, 2.63 mmol, 1.0 eq.) and K2CO3 (910 mg, 6.58 mmol, 2.5 eq.) in a 1:1 mix of THF-
D2O (14 mL) in a 30 mL Parr Reactor.  The Parr reactor was sealed, purged with N2(g) and 
pressurised with D2(g) (8 bar).  The reaction was stirred at rt for 16h.  Then, the pressure was 
released and the suspension was filtered through Celite® and washed with CH2Cl2 (3 x 15 
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mL).  The filtrate was concentrated under reduced pressure to give a solid residue that was 
dissolved in CH2Cl2 (10 mL).  Then, oxalyl chloride (265 µL, 3.16 mmol, 1.2 eq.) and DMF (2 
drops) were added and the resulting solution was stirred at rt for 1 h.  The reaction was 
concentrated under reduced pressure and CH2Cl2 (10 mL), Et3N (857 µL, 6.58 mmol, 2.5 eq.) 
and MeOH (1.0 mL) were added sequentially.  The resulting solution was stirred at rt for 10 
min. The aqueous layer was extracted with CH2Cl2 (2 x 10 mL).  The combined organic layers 
were dried (MgSO4) and concentrated under reduced pressure to give the crude product.  
Purification by flash column chromatography with 1:1 petrol-EtOAc as eluent gave methyl-
2,5-d2-nicotinate 2d (293 mg,72%) as a pale yellow solid, RF (1:1 petrol-EtOAc) 0.3; 1H NMR 
(400 MHz, CDCl3) δ (ppm) 8.79 (s, 1H), 8.31 (s, 1H), 3.97 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 
(ppm) 165.8 (s), 153.4 (s), 150.6 (t, J = 28.1 Hz), 137.0 (s), 125.9 (s), 123.0 (t, J = 25.4 Hz), 
52.44 (s); MS (ESI) m/z 140 [(M + H)+, 100]; HRMS (ESI) m/z [M + H]+ calculated for C7H6-
D2NO2 140.0675, found 140.0681 (−4.8 ppm error). 
 
Methyl-2,5-d2-nicotinate 2e 
 
5% Pd/C (50 mg, 10 wt%) was added to a stirred suspension of 2,5-dichloronicotinic acid 
(500 mg, 2.63 mmol, 1.0 eq.) and K2CO3 (910 mg, 6.58 mmol, 2.5 eq.) in a 1:1 mix of THF-
D2O (14 mL) in a 30 mL Parr Reactor.  The Parr reactor was sealed, purged with N2(g) and 
pressurised with D2(g) (8 bar).  The reaction was stirred at rt for 16h.  Then, the pressure was 
released and the suspension was filtered through Celite® and washed with CH2Cl2 (3 x 15 
mL).  The filtrate was concentrated under reduced pressure to give a solid residue that was 
dissolved in CH2Cl2 (10 mL).  Then, oxalyl chloride (265 µL, 3.16 mmol, 1.2 eq.) and DMF (2 
drops) were added and the resulting solution was stirred at rt for 1 h.  The reaction was 
concentrated under reduced pressure and CH2Cl2 (10 mL), Et3N (857 µL, 6.58 mmol, 2.5 eq.) 
and MeOH (1.0 mL) were added sequentially.  The resulting solution was stirred at rt for 10 
min. The aqueous layer was extracted with CH2Cl2 (2 x 10 mL).  The combined organic layers 
were dried (MgSO4) and concentrated under reduced pressure to give the crude product.  
Purification by flash column chromatography with 1:1 petrol-EtOAc as eluent gave methyl-
2,5-d2-nicotinate 2e (253 mg, 62%) as a pale yellow solid, RF (1:1 petrol-EtOAc) 0.3; 1H NMR 
(400 MHz, CDCl3) δ (ppm) 8.79 (s, 1H), 8.31 (s, 1H), 3.97 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 
(ppm) 165.8 (s), 153.4 (s), 150.6 (t, J = 28.1 Hz), 137.0 (s), 125.9 (s), 123.0 (t, J = 25.4 Hz), 
52.44 (s); MS (ESI) m/z 140 [(M + H)+, 100]; HRMS (ESI) m/z [M + H]+ calculated for C7H6-
D2NO2 140.0675, found 140.0677 (−1.8 ppm error). 
 
Methyl 2,4,5,6-d4-nicotinate  
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A solution of 3-bromo-2,4,5,6-d4-pyridine N-oxide S3 (1.00 g, 6.17 mmol), K2CO3 (1.10 g, 
8.02 mmol, 1.3eq.), PdCl2(dppf) (244 mg, 0.31 mmol,5 mol%) and MeOH (30 mL) was heated 
to 75 °C under CO(g) (4 Bar) for 4 h. The reaction was allowed to cool and concentrated 
under reduced pressure to afford the crude product.  The residue was dissolved in CH2Cl2 
(30 mL) and PCl3 (2.0 mL) was added.  Then,  the reaction was  heated to 40 °C for 2 h. The 
reaction was allowed to cool and quenched by careful addition onto ice. The resulting 
solution was adjusted to pH > 7 by addition of NaHCO3(s) and extracted with CH2Cl2 (3 × 50 
mL). The combined extracts were concentrated under reduced pressure to afford the crude 
product. Purification by flash column chromatography (1:1 hexane-EtOAc) gave methyl 
2,4,5,6-d4-nicotinate (644 mg, 74%) as a pale yellow solid, RF (1:1 hexane-EtOAc) 0.3; 1H 
NMR (400 MHz, CDCl3) δ (ppm) 3.95 (s, 3H); 13C NMR (101 MHz, CDCl3) δ (ppm) 165.7 (s), 
153.0( t, J = 27.0 Hz), 150.6 ( t, J = 28.5 Hz), 136.6 (t, J = 26.0 Hz), 125.8 (s), 122.8  (t, J = 24.7 
Hz), 52.4 (s); MS (ESI) m/z 142 [(M + H)+, 100]; HRMS (ESI) m/z [M + H]+ calculated for C7H3-
D4NO2 142.0806, found 142.0808 (+1.6 ppm error). 
 
d11-2,4,6-trimethylaniline 
 
Acetic acid (1.80 mL) was added dropwise to a stirred solution of d11-nitromesitylene (783 
mg, 4.45 mmol, 1.0 eq.) and zinc powder (1.47 g, 22.25 mmol, 5.0 eq.) in EtOH (15 mL) at 0 
°C.  The resulting solution was warmed to rt and stirred at rt for 5 h.  Then, 1 M NaOH(aq) 
(10 mL) was added and the mixture was extracted with hexane (3 x 15 mL).  The combined 
organic layers were dried (MgSO4) and concentrated under reduced pressure to give d11-
2,4,6-trimethylaniline (583 mg, 90 %) as an orange oil, 1H NMR (400 MHz, CDCl3) δ 3.37 (br 
s, 2H, NH2); 13C NMR (100.6 MHz, CDCl3) δ 140.0 (CNH2), 128.7 (t, J = 22 Hz, CD), 126.9 (s), 
121.7 (s), 19.4 (sept., J = 20 Hz, CD3), 16.7 (sept, J = 20 Hz, CD3); MS (ESI) m/z 147 [(M + H)+, 
100]; HRMS m/z [M + H]+ calcd for C9H3D11N 147.1817, found 147.1819 (+0.3 ppm error).  
Spectroscopic data consistent with those reported in the literature.(4) 
 
d22-2,4,6-Trimethyl-N -[2-[(2,4,6-trimethylphenyl)imino]ethylidene]aniline 
N
CD3
CD3D3C
D
D
N
D3C
CD3
D
CD3
D
 
Glyoxal (160 µL of a 40 w/w% in H2O, 1.37 mmol, 1.0 eq.) and formic acid (2 drops) were 
added sequentially to a stirred solution of d11-mesitylaniline (400 mg, 2.74 mmol, 2.0 eq.) in 
MeOH at rt.  The resulting solution was stirred at rt for 16 h during which time a yellow 
precipitate formed.  The precipitate was filtered, washed with MeOH and dried under 
vacuum to give the ethylenediimine (293 mg, 68%) as a yellow crystalline solid, 1H NMR (400 
MHz, CDCl3) δ 8.12 (s, 2H); 13C NMR (100.6 MHz, CDCl3) δ 163.4 (s), 147.5 (s), 134.0 (s), 
128.7 (t, J = 22 Hz, CD), 126.4 (s), 19.9 (sept., J = 20 Hz, CD3), 17.3 (sept, J = 20 Hz, CD3); MS 
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(ESI) m/z 337 [(M + Na)+, 30], 315 [(M + H)+, 100]; HRMS m/z [M + H]+ calcd for C20H3D22N2  
315.3393, found 315.3378 (+4.7 ppm error). 
 
d22-1,3-Bis-(2,4,6-trimethylphenyl)imidazolium chloride (d22-IMes.HCl) 
 
A solution of paraformaldehyde (32 mg, 1.05 mmol, 1.1 eq.) in 4 M HCl(dioxane) (0.36 mL, 1.43 
mmol, 1.5 eq.) was added dropwise to a stirred solution of the diimine (300 mg, 0.95 mmol, 
1.0 eq.) in EtOAc (10 mL) at rt under N2.  The resulting solution was stirred at rt for 16 h 
during which time an off white precipitate formed.  Then, the precipitate was filtered, 
washed with EtOAc and dried under vacuum to give d22-IMes.HCl (291 mg, 81%) as a white 
powder, 1H NMR (400 MHz, CDCl3) δ 10.21 (br s, 1H, NCH), 7.66 (s, 2H, CH); 13C NMR (100.6 
MHz, CDCl3) δ 141.0 (s), 139.4 (s), 133.9 (s), 130.7 (s), 129.6 (t, J = 24 Hz, CD), 124.6 (s), 20.2 
(sept., J = 19 Hz, CD3), 16.8 (sept, J = 19 Hz, CD3);  MS (ESI) m/z 327 [(M − Cl)+, 100]; HRMS 
m/z calcd for C21H3D22N2 (M − Cl)+ 327.3393, found 327.3376 (+4.8 ppm error). 
 
d3-1,3-Bis-(2,4,6-trimethylphenyl)imidazolium chloride (d3-IMes.HCl) 
 
K2CO3 (21 mg, 0.15 mmol, 0.05 eq.) was added to a stirred solution of IMes.HCl (1.02 g, 3.00 
mmol, 1.0 eq.) in D2O (6 mL) at rt.  The resulting solution was heated at 100 °C for 16 h. 
Then, solvent was removed under reduced pressure to give the crude product.  The solid 
was washed with EtOAc to give d3-IMes.HCl (1.00 g, 97%, 96% deuterium incorporation by 
1H NMR spectroscopy) as a white powder, 1H NMR (400 MHz, CDCl3) δ 7.02 (s, 4H), 2.34 (s, 
6H), 2.18 (s, 12H); 13C NMR (100.6 MHz, CDCl3) δ 141.4 (s), 134.1 (s), 130.6 (s), 130.0 (s), 
130.5 (s), 129.9 (s), 124.2 (t, J = 25 Hz, CD), 21.2 (s), 17.7(s);  MS (ESI) m/z 308 [(M)+, 100]; 
HRMS m/z calcd for C21H23D3N2 (M)+ 308.2206, found 308.2213 (−2.3 ppm error). Contains 
ca. 4% IMes.HCl as characterised by 1H NMR (400 MHz, CDCl3) δ 10.82 (s, 0.04H, NCH), 7.64 
(s, 0.04H). 
 
d25-1,3-Bis-(2,4,6-trimethylphenyl)imidazolium chloride (d25-IMes.HCl) 
 
 
K2CO3 (10 mg, 0.07 mmol, 0.05 eq.) was added to a stirred solution of d22-IMes.HCl(5) (500 
mg, 1.38 mmol, 1.0 eq.) in D2O (10 mL) at rt.  The resulting solution was heated at 100  °C 
for 16 h. Then, solvent was removed under reduced pressure to give the crude product.  The 
solid was washed with EtOAc to give d25-IMes.HCl (490 mg, 97%) as a white powder, 13C 
NMR (100.6 MHz, CDCl3) δ 141.1 (s), 139.5 (t, J = 18 Hz , CD), 133.9 (s), 130.7 (s), 129.6 (t, J = 
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27 Hz, CD), 124.4 ((t, J = 29 Hz, CD), 20.2 (sept., J = 29 Hz, CD3) 16.8 (sept., J = 29 Hz, CD3); 
MS (ESI) m/z 330 [(M− Cl)+, 100]; HRMS m/z calcd for C21D25N2 (M − Cl)+ 330.3587, found 
330.3590 (+3.1 ppm error). 
 
[IrCl(COD)(d2-IMes)] 
KOtBu (62 mg, 0.55 mmol, 2.4eq.) was added to a stirred solution of d3-IMes.HCl (172 mg, 
0.50 mmol, 2.2 eq.) in THF at rt under N2.  The resulting suspension was stirred at rt for 30 
min.  Then, a solution of [Ir(COD)Cl]2 (154 mg, 0.23 mmol, 1.0 eq.) was added and the 
resulting solution was stirred at rt for 2 h.  The solvent was removed under reduced 
pressure to give the crude product.  Purification by flash column chromatography on silica 
with CH2Cl2 as eluent gave [IrCl(COD)(d2-IMes)] (112 mg, 76%) as a yellow crystalline solid, Rf 
(CH2Cl2) 0.2; 1H NMR (400 MHz, CDCl3) δ 7.04 (s, 2H), 7.01 (s, 2H), 4.21-4.16 (m, 2H), 3.03-
2.99 (m, 2H), 2.39 (br s, 12H), 2.19 (s, 6H), 1.79-1.65 (m, 4H), 1.41-1.28 (m, 4H); 13C NMR 
(100.6 MHz, CDCl3) δ 180.7 (s), 138.6 (s), 137.3 (s), 136.0 (s), 134.4 (s), 129.5 (s), 128.1 (s), 
123.2 (t, J = 18 Hz, CD), 82.6 (s),  51.5 (s), 33.5 (s), 28.9 (s), 21.2 (s), 19.7 (s), 18.2 (s);  MS 
(ESI, CH3CN) m/z 607 [(M(193Ir) – Cl)+, 40], 605 [(M(191Ir) – Cl)+, 20]; HRMS in CH3CN m/z 
calcd for C29H34D2193IrN2 (M – Cl)+ 607.2633, found 607.2638 (−3.8 ppm error). 
 
[IrCl(COD)(d22-IMes)] 
KOtBu (27 mg, 0.24 mmol, 2.4eq.) was added to a stirred solution of d22-IMes.HCl (75 mg, 
0.22 mmol, 2.2 eq.) in THF at rt under N2.  The resulting suspension was stirred at rt for 30 
min.  Then, a solution of [Ir(COD)Cl]2 (67 mg, 0.10 mmol, 1.0 eq.) was added and the 
resulting solution was stirred at rt for 2 h.  The solvent was removed under reduced 
pressure to give the crude product.  Purification by flash column chromatography on silica 
with CH2Cl2 gave [IrCl(COD)(d22-IMes)] (78 mg, 56%) as a yellow crystalline solid, Rf (CH2Cl2) 
0.2; 1H NMR (400 MHz, CDCl3) δ 6.88 (s, 2H), 4.10-4.05 (m, 2H), 2.91-2.88 (m, 2H), 1.66-1.51 
(m, 4H), 1.30-1.12 (m, 4H); 13C NMR (100.6 MHz, CDCl3) δ 180.7 (s), 138.4 (s), 137.1 (s), 
136.1 (s), 134.2 (s), 129.3 (t, J = 23 Hz, CD), 127.9 (t, J = 24 Hz, CD),, 123.3 (s), 82.5 (s), 51.4 
(s), 33.5 (s), 29.0 (s), 20.3(sept., J = 22 Hz, CD3), 18.8 (sept., J = 20 Hz, CD3), 17.6 (sept., J = 22 
Hz, CD3); MS (ESI, CH3CN) m/z 668 [(M(193Ir) – Cl + CH3CN)+, 100], 666 [(M(191Ir) – Cl + 
CH3CN)+, 60], 627 [(M(193Ir) – Cl)+, 50], 625 [(M(191Ir) – Cl)+, 30]; HRMS in CH3CN m/z calcd 
for C31H17D22193IrN3 (M – Cl + CH3CN)+ 668.4164, found 668.4172 (+5.0 ppm error). 
 
[IrCl(COD)(d24-IMes)] 
KOtBu (62 mg, 0.55 mmol, 2.4eq.) was added to a stirred solution of d25-IMes.HCl (183 mg, 
0.50 mmol, 2.2 eq.) in THF at rt under N2.  The resulting suspension was stirred at rt for 30 
min.  Then, a solution of [Ir(COD)Cl]2 (154 mg, 0.23 mmol, 1.0 eq.) was added and the 
resulting solution was stirred at rt for 2 h.  The solvent was removed under reduced 
pressure to give the crude product.  Purification by flash column chromatography on silica 
with CH2Cl2 as eluent gave [IrCl(COD)(d24-IMes)] (124 mg, 81%) as a yellow crystalline solid, 
Rf (CH2Cl2) 0.2; 1H NMR (400 MHz, CDCl3) δ 4.19-4.17 (m, 2H), 3.01-2.99 (m, 2H), 1.75-1.68 
(m, 4H), 1.40-1.23 (m, 4H); 13C NMR (100.6 MHz, CDCl3) δ 180.6 (s), 138.4 (s), 137.1 (s), 
136.1 (s), 134.2 (s), 129.3 (t, J = 22 Hz, CD), 127.8 (t, J = 25 Hz, CD), 123.0 (t, J = 26 Hz), 82.5 
(s), 77.3 (s),  51.4 (s), 33.5 (s), 29.0 (s), 20.4 (sept., J = 20 Hz, CD3), 18.8 (sept., J = 20 Hz, CD3), 
17.4 (sept., J = 21 Hz, CD3); MS (ESI) m/z 629 [(M(193Ir) – Cl)+, 40], 627 [(M(191Ir) – Cl)+, 20]; 
HRMS m/z calcd for C29H12D24193IrN2 (M – Cl)+ 629.4010, found 629.4000 (+4.9 ppm error). 
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Contains ca. 10% [IrCl(COD)(d22-IMes)] as characterised by 1H NMR (400 MHz, CDCl3) δ 6.99 
(s, 0.20H). 
 
 
3,5-d2-pyridazine 3a 
 
Using general procedure A, 3,5-dichloropyridazine (1.0 g, 6.7 mmol, 1.0 eq.), K2CO3 (2.8 g, 20 
mmol, 3 eq.),  5% Pd/C (50 mg, 10 wt%) and D2 (8 bar). in THF (5 mL) and D2O (5 mL) gave 
the crude product.  Purification by flash column chromatography with EtOAc as eluent to 
give 3,5-d2-pyridazine 3a (240 mg, 44%) as a light yellow oil; 1H NMR (400 MHz, CDCl3) δ 
9.07 (s, 1H), 7.38 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 151.5 (s), 151.2 (t, J = 28.0 Hz), 126.1 
(s), 126.0 (t, J = 25.8 Hz); MS (ESI) m/z 83 [(M + H)+, 100]; HRMS (ESI) m/z [M + H]+ 
calculated for C4H3D2N2 83.0573, found 83.0575 (‒3.6 ppm error). 
 
2,5-d2-pyrimidine 4a 
 
 
To a suspension of 2,5-dichloropyrimidine (500 mg, 3.4 mmol, 1.0 eq.) and K2CO3 (1.4 g, 10 
mmol, 3 eq.) in THF (5 mL) and D2O (5 mL)  in a 30 mL Parr reactor was added 5% Pd/C (50 
mg, 10 wt%). The reactor was sealed, purged with N2, then pressurised with D2 (8 bar). The 
reaction mixture was stirred at room temperature for 1 hour. The pressure was released 
and the suspension was filtered through Celite® and washed with diethyl ether (20 mL). The 
filtrate was washed with brine (20 mL), dried over MgSO4 then acidified with HCl (2 M in 
diethyl ether, 2 mL). The resulting suspension was decanted to leave an oily residue which 
solidified under a stream of nitrogen. This solid was dissolved in methanol-d4 (4 mL) and 
passed through a plug of basic alumina to give a solution of 2,5-d2-pyrimidine 4a (0.565 M in 
methanol-d4), 1H NMR (400 MHz, MeOD) δ 8.81 (s, 2H); 13C NMR (101 MHz, MeOD) δ 158.8 
(t, J = 31.2 Hz), 158.3 (s), 123.2 (t, J = 26.1 Hz); MS (ESI) m/z 83 [(M + H)+, 100]. The 
concentration was determined by quantitative 1H NMR with potassium phthalate 
monobasic as an internal standard. 
 
2,5-d2-pyrazine 5a 
 
To a suspension of 2,5-dichloropyrazine (500 mg, 3.4 mmol, 1.0 eq.) and K2CO3 (925 mg, 6.7 
mmol, 2 eq.) in THF (5 mL) and D2O (5 mL)  in a 30 mL Parr reactor was added 5% Pd/C (50 
mg, 10 wt%). The reactor was sealed, purged with N2, then pressurised with D2 (8 bar). The 
reaction mixture was stirred at room temperature for 1 hour. The pressure was released 
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and the suspension was filtered through Celite® and washed with diethyl ether (20 mL). The 
filtrate was washed with brine (20 mL), dried over MgSO4 then acidified with HCl (2 M in 
diethyl ether, 2 mL). The resulting suspension was decanted to leave an oily residue which 
solidified under a stream of nitrogen. This solid was dissolved in methanol-d4 (4 mL) and 
passed through a plug of basic alumina to give a solution of 2,5-d2-pyrazine 5a (0.088 M in 
methanol-d4); 1H NMR (400 MHz, MeOD) δ 8.64 (s, 2H); 13C NMR (101 MHz, MeOD) δ 146.1 
(s), 145.9 (t, J = 28.2 Hz); MS (ESI) m/z 83 [(M + H)+, 100]. The concentration was determined 
by quantitative 1H NMR with potassium phthalate monobasic as an internal standard. 
 
Methyl 2,5-dichloroisonicotinate S9 
 
To a solution of 2,5-dichloroisonicotinic acid (500 mg, 2.6 mmol, 1.0 eq.) in methanol (5 mL) 
and diethyl ether (5 mL) was added (trimethylsilyl)diazomethane solution (2.6 mL, 2.0 M in 
diethyl ether, 2 eq.). The reaction mixture was stirred at room temperature for 30 minutes, 
then concentrated under reduced pressure and purified by flash column chromatography 
with 4:1 petrol-EtOAc as eluent to give methyl 2,5-dichloroisonicotinate S9 (518 mg, 97%) as 
a colourless solid, 1H NMR (400 MHz, CDCl3) δ 8.43 (s, 1H), 7.65 (s, 1H), 3.93 (s, 3H); 13C NMR 
(101 MHz, CDCl3) δ 163.2 (s), 150.9 (s), 149.9 (s), 139.2 (s), 129.1 (s), 125.1 (s), 53.3 (s); MS 
(ESI) m/z 206 [(M + H)+, 100], 208 [84]; HRMS (ESI) m/z [M + H]+ calculated for C7H6Cl2NO2 
205.9770, found 205.9766 (+2.9 ppm error). 
 
Ethyl 2,5-d2-isonicotinate S10 
 
To a suspension of methyl 2,5-dichloroisonicotinate (500 mg, 2.4 mmol, 1.0 eq.) and K2CO3 
(850 mg, 6.2 mmol, 2.5 eq.) in EtOD (10 mL) in a 30 mL Parr reactor was added 5% Pd/C (50 
mg, 10 wt%). The reactor was sealed, purged with N2, then pressurised with D2 (8 bar).  The 
reaction mixture was stirred at room temperature for 4 hours. The pressure was released 
and the suspension was filtered through Celite® and washed with EtOH. The filtrate was 
concentrated under reduced pressure and purified by flash column chromatography with 
1:1 petrol-EtOAc as eluent to give ethyl 2,5-d2-isonicotinate S10 (268 mg, 72%) as a 
colourless oil, 1H NMR (400 MHz, CDCl3) δ 8.75 (s, 1H), 7.82 (s, 1H), 4.39 (q, J = 7.1 Hz, 2H), 
1.39 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 165.2 (s), 150.6 (s), 150.3 (t, J = 27.3 Hz), 
137.6 (s), 122.8 (s), 122.7 (t, J = 25.6 Hz), 61.9 (s), 14.3 (s); MS (ESI) m/z 154 [(M + H)+, 100], 
126 [64]; HRMS (ESI) m/z [M + H]+ calculated for C8H8D2NO2 154.0832, found 154.0832 (‒0.3 
ppm error). 
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Methyl 2,5-d2-isonicotinate S11 
 
A suspension of ethyl 2,5-d2-isonicotinate (268 mg, 1.8 mmol, 1.0 eq.) and K2CO3 (25 mg, 
0.18 mmol, 0.1 eq.) in MeOD (3 mL) was heated to 110 °C under microwave irradiation for 1 
hour. The reaction mixture was concentrated under reduced pressure and purified by flash 
column chromatography with 2:1 petrol-EtOAc as eluent to give methyl 2,5-d2-isonicotinate 
XX (124 mg, 51%) as a colourless oil; 1H NMR (400 MHz, CDCl3) δ 8.74 (s, 1H), 7.80 (s, 1H), 
3.92 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 165.6 (s), 150.6 (s), 150.3 (t, J = 27.8 Hz), 137.2 (s), 
122.7 (s), 122.6 (t, J  = 25.7 Hz), 52.8 (s); MS (ESI) m/z 140 [(M + H)+, 100]; HRMS (ESI) m/z 
[M + H]+ calculated for C7H6D2NO2 140.0675, found 140.0680 (‒3.5 ppm error). 
 
2,5-d2-isonicotinamide 6a 
 
A solution of methyl 2,5-d2-isonicotinate (30 mg, 0.22 mmol, 1.0 eq.) in ammonia (5 mL, 7 N 
solution in methanol) was stirred at room temperature for 24 hours. The reaction mixture 
was concentrated and purified by flash chromatography with 1:9 MeOH-CH2Cl2 as eluent to 
give 2,5-d2-isonicotinamide 6a (27 mg, 100%) as a colourless solid, 1H NMR (400 MHz, 
CD3OD) δ  8.69 (s, 1H), 7.82 (s, 1H), 4.97 (s, 2H); 13C NMR (101 MHz, CD3OD) δ 169.7 (s), 
150.9 (s), 150.6 (t, J = 27.9 Hz), 143.3 (s), 123.1 (s), 122.9 (t, J = 26.8 Hz); MS (ESI) m/z 125 
[(M + H)+, 100]; HRMS (ESI) m/z [M + H]+ calculated for C6H5D2N2O 125.0678, found 
125.0680 (‒1.1 ppm error). 
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2.  NMR polarization transfer experiments 
2.1 Polarization transfer methods 
The polarization transfer experiments that are reported were conducted in either an NMR 
tube that was equipped with a Young’s Tap (Method A) or using an automated polarizer 
(Method B). 
 
Method A 
Samples for these polarization transfer experiments were based on a 5 mM solution of 
[IrCl(COD)(IMes)] and substrate in methanol-d4 or ethanol-d6 (0.6 mL). The samples were 
degassed prior to the introduction of parahydrogen at the required pressure. Samples were 
then shaken for 10 s in the specified fringe field of an NMR spectrometer before being 
rapidly transported into the magnet for subsequent interrogation by NMR spectroscopy. 
 
Method B 
For the automated polarizer measurements, samples consisted of [IrCl(COD)(IMes)] and the 
substrate in methanol-d4 solution (3mL). A schematic representation of the polarizer used 
for flow measurements is shown in Figure S1. The Mixing Chamber (MC) is housed within a 
tuneable copper coil (0.5 to ±150 G). The coil was situated in a magnetic field which has the 
components x 4.9 – 5.1 G, y 3.3 – 3.6 G and z 1.5 – 2.1 G. All magnitudes of the magnetic 
fields in which polarization transfer occurs (PTF) are stated without correction for this local 
field). The MC houses the solvent, catalyst and substrate. Liquid and gas flow is computer-
controlled via the pulse program. As such, the system is entirely automated. 
Parahydrogen is introduced into the MC first to activate the catalyst. Nitrogen gas is used to 
shuttle the hyperpolarized solution from the MC to the NMR probe head for measurement. 
The transportation time was calibrated to 2.9 s. A further delay of 0.5 s was allowed for 
settling of the sample prior to signal acquisition (1 s).  
S29 
 
 
Fig. S1: Schematic representation of the polarizer, the hyperpolarization process and its subsequent 
NMR analysis. 
 
2.2 1H Enhancement factors calculations and statistical analysis 
 
For calculation of the enhancement of 1H NMR signals the following formula was used: 
 
E ൌ SIሺpolሻSIሺunpolሻ 
 
Where, E = enhancement, SI(pol) = signal of polarized sample, SI(unpol) = signal of 
unpolarized (reference) sample. Experimentally, both spectra were recorded on the same 
sample using identical acquisition parameters, including the receiver gain. The raw integrals 
of the relevant resonances in the polarized and unpolarized spectra were then used to 
determine the enhancement levels.  
Errors corresponding to the determination of the enhancement of individual sites have been 
calculated using the standard deviation formula 
ߝ ൌ ඨ∑ሺݔ െ ̅ݔሻ
ଶ
݊  
where ̅ݔ is the sample mean average of the enhancements obtained after performing 
several experiments on the same sample and n is the number of experiments (typically 
between 5 and 7). The values ߝ obtained for each site were used in the calculation of the 
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errors for the total enhancement using the well-known method for the propagation of 
uncertainty.  
 
2.3 Representative 1H NMR spectra of the SABRE effect in deuterated agents 
 
 
Fig. S2: l) Thermal 1H NMR spectrum of [IrCl(COD)(IMes)], nicotinamide 1 under 3 bar H2; b) 1H NMR 
spectrum of  1 recorded after SABRE under 3 bar pH2.  
 
 
Fig. S3: a) Thermal 1H NMR spectrum of [IrCl(COD)(IMes)], 4,6-d2-nicotinamide 1f under 3 bar H2; b) 
1H NMR spectrum of  1f recorded after SABRE under 3 bar pH2.  
 
  
Fig. S4: a) Thermal 1H NMR spectrum of [IrCl(COD)(IMes)], methyl nicotinate 2 under 3 bar H2; b) 1H 
NMR spectrum of  2 recorded after SABRE under 3 bar pH2.  
a) 
a) 
a) 
b) 
b) 
b) 
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Fig. S5: a) Thermal 1H NMR spectrum of [IrCl(COD)(IMes)], methyl-4,6-d2-nicotinate 2b under 3 bar 
H2; b) 1H NMR spectrum of  2b recorded after SABRE under 3 bar pH2.  
 
2.4 Polarisation transfer results for the specified IMes catalysts 
 
Table S1: Polarisation transfer levels and T1 values of methyl-4,6-d2-nicotinate 2b achieved via 
transfer with the specified deuterated catalysts of form [IrCl(COD)(NHC)] and 3 bar p-H2. 
 
 
 
 
Carbene Ligand 
Methanol-d4 Ethanol-d6 
Site T1(eff., with 
cat.) (s) 
Polarization 
(%) 
Site T1(eff., with 
cat.) (s) 
Polarization 
(%) 
 
IMes 
H-2 : 5.8 
H-5 : 21.1 
H-2: 10.9 
H-5: 9.4 
H-2 : 5.9 
H-5 : 15.5 
H-2: 7.5 
H-5: 5.5 
 
d2-IMes 
H-2 : 5.8 
H-5 : 20.9 
H-2: 10.1 
H-5: 9.5 
H-2 : 5.5 
H-5 : 15.6 
H-2: 9.3 
H-5: 8.2 
N
CD3
CD3
D3C
D
D
N
D3C D
CD3
DD3C  
d22-IMes 
H-2: 7.7 
H-5: 26.6 
H-2: 24.1 
H-5: 19.9 
H-2 : 7.7 
H-5 :17.2 
H-2: 26.8 
H-5: 16.6 
N
CD3
CD3
D3C
D
D
N
D3C D
CD3
DD3C
DD
 
d24-IMes 
H-2 : 9.5 
H-5 : 33.5 
H-2 : 18.6 
H-5 : 16.5 
H-2 : 7.5 
H-5 : 19.3 
H-2: 13.3 
H-5: 8.2 
a) b) 
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2.5 Effect of p-H2 pressure on polarisation transfer with [IrCl(COD)(d22-IMes)] 
p-H2 Pressure (bar) 
Methanol-d4 Ethanol-d6 
Polarization (%) Polarization (%) 
3.0 H2 : 24.1H5 : 19.9 
H2: 26.8
H5: 16.6 
4.0 H2: 26.4H5: 23.3 
H2: 39.1
H5: 25.2 
5.5  H2: 28.5H5: 23.4 
H2: 41.7
H5: 26.5 
Table S2: Polarisation levels achieved with methyl-4,6-d2-nicotinate 2b in conjunction with 
[IrCl(COD)(d22-IMes)]. 
 
2.6 Use of methyl-2,4,5,6-d4 nicotinate as a co-substrate 
Methyl-2,4,5,6-d4-nicotinate  was used as a co-substrate to further reduce spin dilution in 
the active catalyst to achieve optimal polarisation of 2b.  A sample containing 5 mM of 
[IrCl(COD)(d22-IMes)], 1 equivalent of  2b and 3 equivalents of  methyl-2,4,5,6-d4-nicotinate 
in methanol-d4 (0.6 mL) was prepared and exposed to increasing pressures of p-H2 as shown 
in Table S3. 
p-H2 Pressure (bar) Polarization (%)
3.0 H2: 40.0 H5: 35.1 
4.5 H2: 46.3 H5: 39.7 
5.5  H2: 49.8 H5: 39.7 
Table S3: Polarisation levels achieved with [IrCl(COD)(d22-IMes)], 1 eq. methyl-4,6-d2-nicotinate 2b 
and 3 eq. methyl-2,4,5,6-d4-nicotinate. 
 
2.7 Kinetic behaviour of 2b with [IrCl(COD(NHC)] under H2 
The kinetic behaviour of 2b with [IrCl(COD)(IMes)] and [IrCl(COD)(d22-IMes)] under 3 bar H2 
was examined using exchange spectroscopy, as  follows. 
A series of exchange spectroscopy (EXSY) measurements were performed to probe the 
dynamic behaviour of these systems. This process involved the selective excitation of a 
single resonance and the subsequent measurement of a 1H NMR spectrum at time, t, after 
the initial pulse. The resulting measurements consisted of a series of data arrays such that t 
is varied typically between 0.1 to 1.0 s, to encode the reaction profile. The precise values 
were varied with temperature to suit the speed of the process. Data was collected for a 
range of temperatures and sample concentrations. Integrals for the interchanging peaks in 
the associated 1H EXSY spectra were obtained and converted into a percentage of the total 
detected signal.  
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These data were then analysed as a function of the mixing time according to a differential 
kinetic model [10]. Rates of exchange were determined by employing a Runge-Kutta(6, 7) 
scheme to solve the system of differential equations and a Levenberg–Marquardt 
algorithm(8, 9) to minimize the sum of the residuals in the associated least mean squares 
analysis. The theoretical model used to fit the experimental EXSY data involved a two-site 
exchange (A ↔ B), as expressed by the equations below: 
 
െ݀ܣ݀ݐ ൌ 	െܭ௔௕ ∗ ܣ ൅	ܭ௕௔ ∗ ܤ 
െ݀ܤ݀ݐ ൌ ൅ܭ௔௕ ∗ ܣ െ ܭ௕௔ ∗ ܤ 
An example of typical build-up/decay curves obtained from the integration of the 
experimental EXSY data, together with the corresponding fitted data is presented below. 
 
Fig. S6: Evolution of the ligand loss process as a function of time. 
 
 [IrCl(COD)(IMes)] [IrCl(COD)(d22-IMes)] 
Temperature (K) Rate (s−1) Rate (s−1) 
298 10.0 ± 0.1 9.1 ± 0.1 
293 5.1 ± 0.1 4.8 ± 0.1 
283 1.3 ± 0.1 1.2 ± 0.1 
273  0.3 ± 0.1 0.2 ± 0.1 
263 No Exchange No Exchange 
Table S4: Rate of equatorial ligand build up in solution. 
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2.8 T1 relaxation data for 2b in ethanol-d6:D2O solvent mixtures 
The relaxation rate of 2b in varying mixtures of ethanol-d6:D2O was recorded using inversion recovery at 
9.4 T.  These data are presented in Fig. S6. 
 
Fig. S7. T1 relaxation data for 2b as a function of ethanol-d6:D2O solvent mixture composition (%). 
2.9 T1 relaxation data in H2O solution containing 5% D2O 
The relaxation of each of the substrates was also monitored in 95% H2O 5% D2O solution using an inversion 
recovery sequence with water suppression at 9.4 T. These data are presented in Table s5. 
Agent T1 Relaxation Time (s) (Under O2) 
Agent T1 Relaxation Time (s) 
1 
 
H-2: 
H-4: 
H-5: 
H-6: 
5.9 
4.6 
4.6 
5.9 
 
2c 
 
H-2: 
H-5: 
6.5 
9.7 
1a 
 
H-4: 
H-5: 
4.2 
4.6 
 
2d H-5: H-6: 
5.7 
5.0 
1b 
 
H-5: 
H-6: 
5.4 
4.8 
 
2e 
 
H-4: 
H-6: 
7.4 
6.6 
1c 
 
H-2: 
H-6: 
5.0 
6.3 
 
3  
H-3/H-6 
H-4/H-5 
7.7 
7.5 
1d 
 
H-2: 
H-4: 
4.8 
6.2 
 
3a H-4 H-6 
9.7 
9.1 
1e 
 
H-4: 
H-6: 
5.4 
5.6 
 
4  
H-2 
H-4/H-6 
H-5 
7.3 
6.9 
6.4 
0
10
20
30
40
50
60
70
0 10 20 30 40 50 60 70 80 90 100
T 1
/ S
% EtOD 
H2
H5
S35 
 
1f 
 
H-2: 
H-5: 
5.6 
8.6 
 
4a  H-4/H-6 8.6 
1g 
 
H-2: 5.8 
 
5  H 7.3 
2 
 
H-2: 
H-4: 
H-5: 
H-6: 
6.0 
4.1 
4.1 
5.1 
 
5a  H-3/H-6 8.5 
2a 
 
H-2: 
H-4: 
H-5: 
H-6: 
6.9 
5.0 
4.2 
5.6 
 
6 
 
H-2/H-6 
H-3/H-5 
4.9 
4.4 
2b 
 
H-2: 
H-5: 
6.6  (4.4) 
9.3  (6.1) 6a  
H-3 
H-6 
6.5 
5.9 
 
Table S5. T1 relaxation times for the specified substrates in 95% H2O 5% D2O solution 
3. SABRE MRI Collection 
The SABRE experiments used the substrate and catalyst concentrations detailed below. Samples were 
prepared containing 1 and 2 in 3.0 ml of deuterated solvent. Arrays of measurements were collected using 
either 5 or 20 equivalents of substrate to 5 mM of iridium. Typical samples reflect the following situations: 
i. 5 mM catalyst + 20 mM substrate (1:4 ratio) in 3.0 ml d4-methanol (MeOD). 
ii. 5 mM catalyst + 20 mM substrate (1: 4 ratio) in 3.0 ml d6-ethanol (EtOD). 
iii. 5 mM catalyst + 100 mM substrate (1: 20 ratio) in 3.0 ml d6-ethanol (EtOD). 
 
It should be noted that when a 100 mM loading is employed, the d22-IMes catalyst yields 1.15% 
polarisation in 1f and T1 values of 13.2 and 22.1 s respectively. When 2c is examined in the same way the 
T1's change to 16.1 and 24.9 s whilst the average polarisation level becomes 2.6%. In contrast, when IMes 
itself is used, the corresponding T1 values are 10.7, 21.0, 10.3 and 21.6 s whilst the enhancement levels fall 
to 0.9 and 1.55% respectively.  
 
3.2 MRI Instrumentation and Procedures 
3.2.1 MRI instrumentation 
All images have been acquired using a 400 MHz wide-bore vertical Bruker spectrometer, equipped with a 
Avance III console and a Great 60 gradient unit. The maximum amplitude delivered by the microimaging 
gradient set was 1T/m. Detection was done using a 30 mm diameter double resonance (1H-13C) birdcage. 
Unless otherwise stated, hyperpolarisation experiments were performed with the help of an automated 
Bruker polariser (Method B, presented in section 2.2).(10) The measurements performed at pressures 
higher than 3 bar pH2 were done using Method A as presented in section 2.2 and employing a 20 s 
polarisation transfer time. 
 
3.2.2 MRI acquisition methods 
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All images presented here were recorded using a one shot spin echo based acquisition protocol (RARE(11)) 
with slice selective Gaussian pulses with matched bandwidths. For the experiments performed using the 
automated polariser image acquisition parameters were as follows: field of view (FOV) 20 x 20 mm2, matrix 
size 64 x 64, slice thickness 2 mm and 5 mm (for the experiments performed in MeOD and EtOD 
respectively), typical acquisition time 260 ms per image. In the case of the experiments performed using a 
water suppression scheme, the image acquisition parameters were kept the same, except for the FOV (30 x 
30 mm2). 
 
Solvent suppression was accomplished by using a VAPOR (variable power and optimized relaxation 
delays(12)) train of pulses centred on the water resonance, with a wide bandwidth, which covered not only 
the H2O signal but also the signals coming from the residual protons in the deuterated solvents. The total 
duration of the suppression module was 660 ms. 
 
3.2.3 MRI data processing and statistical analysis 
All results were processed using Bruker software (Paravision 5.1) and home-developed post processing 
routines written in MATLAB. Prior to Fourier transformation, data were zero-filled once (final matrix size 
128 x 128) and a sine bell squared filter was applied.  
Signal-to-noise values were calculated using the ratio between the mean of the signal and the standard 
deviation of the noise. In most cases the values obtained for the selectively deuterated substrates are 
expressed as relative to the corresponding values obtained for the protio molecule.  
 
3.3 Results 
3.3.1 Image intensity optimisation through selective deuteration 
 
Fig. S8. Images of 20 mM hyperpolarised 1 in MeOD; 1a (left) 1d (centre) and 1f (right). 
 
Fig. S9. Images of 20 mM hyperpolarised 2 in MeOD; 1 (left) 2b (centre) and 2c (right). 
 
3.3.2 Effects of relaxation on image quality 
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In order to probe the effect of relaxation on the image intensity, a set of images of each sample was 
acquired in identical conditions but with variable delays before the transfer of the sample in the magnet. 
The purpose of this was to estimate the effective signal left after various times from the end of the 
polarisation process, as would be required in real life applications (delivery through an injection or 
catheter) in which the delivery speed needs to be adjusted according to clinical requirements.  The waiting 
times employed were adjusted as a function of the substrate’s relaxation rate and were typically between 
0 and 30 s. A centric sampling of the k-space was employed to minimise the effect the transverse 
relaxation might have on the signal.  
 
 
Fig. S10 Images of 20 mM hyperpolarised 1 in MeOD. 1a (left), 1d (centre) and 1f (right) after 5 s (top) and 10 s (bottom) from 
the polarisation transfer process. 
 
Fig. S11 SNR decay as a function of the delay between the polarisation transfer process and image acquisition for 1. 
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Fig. S12 Images of 20 mM hyperpolarised 2 in MeOD. 2 (left), 2b (centre) and 2c (right) after 5 s (top) and 10 s (bottom) from the 
polarisation transfer process. 
 
Fig. S13 SNR decay as a function of the delay between the polarisation transfer process and image acquisition for 2, 2b and 2c. 
 
 
 
 
 
3.3.3 Image contrast optimisation by water and solvent suppression 
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A). B).  
 
C). D).  
Fig. S14 Images of a 5 mm water tube and 100 mM hyperpolarised substrate in EtOD. A). no water suppression, hyperpolarised 
1, B). water suppression on, hyperpolarised 1, C). water suppression on, hyperpolarised 1f and D). water suppression on, 
hyperpolarised 2b. 
A). B).  
C). D).  
Fig. S15 Images of a 5 mm water tube and 100 mM 2b in EtOD. The images were acquired using a water suppression scheme A). 
10 s, B). 15 s, C). 20 s and D). 30 s after the polarisation transfer process.  
 
3.3.4 Effects of pH2 pressure on image quality 
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The effects of pH2 pressure on image intensity and contrast were tested using a pressure resistant tube 
and the substrates 1f and 2b. The results are presented below. 
 
Fig. S16 Images of hyperpolarised 1f. The images were acquired using 3 bar pH2 pressure (left) and 8 bar of pH2 pressure (right) 
in MeOD. SNR: 348 and 3847 respectively.  
 
Fig. S17 Images of water (left), hyperpolarised 1f (centre) and 1f in Boltzmann equilibrium conditions. Catalyst:Substrate ratio 
1:20. SNR: 2384, 3847 and 35 respectively.  
 
Fig. S18 Images of hyperpolarised 2b. The images were acquired under Boltzmann equilibrium conditions (left), hyperpolarised 
in MeOD (centre) and hyperpolarised in EtOD (right). Catalyst:Substrate ratio 1:4. SNR: 9, 1482, 939. 
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